



**Prevalence, awareness, treatment and control of hypertension in a self-selected sub-Saharan African urban population: A cross-sectional study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001217
Article Type:	Research
Date Submitted by the Author:	01-Apr-2012
Complete List of Authors:	Dzudie, Anastase Kengne, Andre; South African Medical Research Council, National Collaborative Programme on Cardiovascular and metabolic Disease; The George Institute for Global Health, Muna, Walinjom Ba, Hamadou Menanga, Alain Kouam Kouam, Charles Abah, Joseph Monkam, Yves; General Hospital of Douala, Department of Internal Medicine Biholong, Christian; General Hospital of Douala, Department of Internal Medicine Mintom, Pierre Kamdem, Felicite; General Hospital of Douala, Department of Internal Medicine Djomou, Armel; General Hospital of Douala, Department of Internal Medicine Ndjebet, Jules; General Hospital of Douala, Department of Internal Medicine Ouambo, Cyrille Luma, Henry; General Hospital of Douala, Department of Internal Medicine Ngu, Kathleen Kingue, Samuel
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine, Epidemiology
Keywords:	Hypertension < CARDIOLOGY, EPIDEMIOLOGY, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts

1  
2  
3 **Prevalence, awareness, treatment and control of hypertension in a self-selected sub-**  
4  
5 **Saharan African urban population: A cross-sectional study**  
6  
7

8 **Short title:** Awareness, treatment and control of hypertension  
9

10 Anastase Dzudie, MD, FESC(1); André Pascal Kengne, MD, PhD(2); Walinjom F.T. Muna, MD,  
11 PhD, FACC(3); Hamadou Ba, MD(1); Alain Menanga, MD (4); Charles Kouam Kouam MD(5);  
12 Joseph Abah, MD(6); Yves Monkam, MD(1); Christian Biholong, MD(1); Pierre Mintom MD(4);  
13 Félicité Kamdem, MD(1); Armel Djomou, MD(1); Jules Ndjebet, MD(1); Cyrille Ouambo, MD,  
14 PhD(1); Henri Luma, MD(1), Katleen Blackett Ngu, MD, FESC(6); Samuel Kingue, MD(6); On  
15 behalf of the CCS investigator group\*.  
16  
17  
18  
19  
20  
21

22 (1) Department of Internal Medicine, Douala General Hospital and Buea Faculty of medicine,  
23 Cameroon  
24  
25

26 (2) NCRP or Cardiovascular and metabolic disease, South African Medical Research Council &  
27 University of Cape Town, Cape Town, South Africa  
28

29 (3) Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, Yaounde,  
30 Cameroon  
31  
32

33 (4) Department of Internal Medicine, Yaounde General Hospital , Cameroon  
34

35 (5) Department of Internal Medicine, Bafoussam Regional Hospital , Cameroon  
36  
37

38 (6) Department of Internal Medicine, Bamenda Military Hospital , North West Region, Cameroon  
39  
40

41 **Correspondence to:** Dr Anastase Dzudie, MD; FESC. Douala General Hospital; PO Box 4856,  
42 Douala General Hospital, Douala – Cameroon, Tel: +(237)79617981; Fax: +(237)33370146; email:  
43 [aitdzudie@yahoo.com](mailto:aitdzudie@yahoo.com)  
44  
45  
46  
47

48 Tables #5; Figures #2.  
49

50 Word count: Abstract (265); Main text excluding reference, figure legend and references (3720)  
51  
52  
53

54 \* Members list in the appendix section  
55  
56  
57  
58  
59  
60

## Abstract

**Objectives.** Hypertension has been established as a major public health problem in Africa, but its specific contributions to disease burden are still incompletely understood. We quantified the burden and determinants of hypertension, detection, treatment and control rates among adults in major cities in Cameroon.

**Design.** Cross-sectional study

**Settings.** Community-based multicenter study in major cities in Cameroon

**Participants.** Participants were self-selected urban dwellers from the Center, Littoral, North-West and West Regions, who attended on May 17th 2011 a screening campaign advertised through mass media.

**Primary and secondary outcomes measures.** Hypertension defined as systolic (and/or diastolic) blood pressure  $\geq 140$  (90) mmHg, or ongoing blood pressure (BP) lowering medications.

**Results.** In all, 2120 participants (1003 women) were included. Among them, 1007 (prevalence rate 47.5%) had hypertension, including 319 (awareness rate 31.7%) who were aware of their status. The prevalence of hypertension increased with age overall and by sex and region. Among aware hypertensive subjects, 191 (treatment rate 59.9%) were on regular BP lowering medication, and among those treated, 47 (controlled rate 24.6%) were at target BP levels (i.e. systolic (and diastolic) BP  $<140$  (90) mmHg). In multivariable logistic regressions analysis, male gender, advanced age, parental history of hypertension, diabetes mellitus, elevated waist, and elevated body mass index (BMI) were the significant predictors of hypertension. Likewise, male gender, high BMI and physical inactivity were associated with poor control.

**Conclusions.** High prevalence of hypertension with low awareness, treatment and control were found in this urban population; these findings are significant and alarming with

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

consideration to the various improvements in the access to healthcare and the continuing efforts to educate communities over the past decades.

Word count - 265

**Key Words:** Hypertension, prevalence, awareness, treatment, control, Cameroon, Africa

For peer review only

## Article summary

### Article focus

- This article quantified the burden and determinants of hypertension, detection, treatment and control rates among adults in major cities in Cameroon, central Africa

### Key messages

- The prevalence of hypertension was very high in this population, coupled with low detection, treatment and control rates.
- Age, gender and excess weight were the main drivers of the high prevalence, while the coincidence of classical cardiovascular risk factors was associated with poor control.

### Strengths and limitations of this study

- Major strengths of this study include the large sample, the multicenter nature, the rigorous data collection on a range of determinants and provision of standardized prevalence figures.
- Limitations include the selection of participants, and hypertension diagnosis based on blood pressure measurement during a single encounter.

## Introduction

Hypertension has been established as a major public health problem worldwide.[1] Several published studies suggest that hypertension is the commonest modifiable risk factor for stroke, congestive heart failure and kidney failure[2-5] in the sub-Saharan African (SSA) region. It is a major contributor to overall mortality risk in adults in the region.[6] Hypertension also seems to be more common in urban than rural population[7] of the SSA region.

Specific risks associated with various blood pressure (BP) readings have largely been established for populations in many parts of the developed world but this is not the case for countries of the developing world including the SSA region. There is considerable evidence that long-term BP lowering to what is considered either normal or optimal levels results in several significant and important health benefits.[8] When established norms for ideal or optimal BP are applied to SSA populations, it becomes very evident that the vast majority of eligible patients do not enjoy the benefits of BP lowering therapies, either because of under-diagnosis or the many other barriers to BP lowering medications prescription, access and compliance in this setting.[1 2] As a case in point, a survey in Cameroon about eight years ago found that only 23% of all individuals with hypertension at the community level were aware of their status.[9] Moreover, only 46% of those aware (11% of all those with hypertension) were on treatment, among whom only 19% (2% of all those with hypertension) achieved expected target BP levels.[9]

There is also evidence that SSA is undergoing very rapid transitions characterized by increasing urbanization, including the adoption of unhealthy lifestyles.[10 11] These transitions are paralleled by changes in the profile of chronic disease risk factors including

1  
2  
3 blood pressure.[7] Recently there has been increasing awareness of the threat that the  
4  
5 looming chronic diseases pose to the health of the population in the Region at different  
6  
7 levels.[12] This increasing awareness has catalyzed initiatives aimed at improving access to  
8  
9 detection and care of chronic diseases including hypertension[13] in many countries of the  
10  
11 region. The pace of the above mutations suggests that, data on the burden of hypertension,  
12  
13 must be updated regularly, in order to provide the reliability needed in drawing-up health  
14  
15 service and policy solutions.  
16  
17

18  
19 The aim of this study was to assess the prevalence and determinants of hypertension, and  
20  
21 including the detection, treatment and control rates, as well as the variability by region and  
22  
23 gender in four major cities of Cameroon.  
24  
25

## 26 27 **Material and methods**

### 28 29 *Study population and settings*

30  
31 This was a cross-sectional population-based study conducted in the regional capitals of the  
32  
33 Centre (Yaounde), Littoral (Douala), North-West (Bamenda) and West (Bafoussam)  
34  
35 administrative regions (out of a total of ten) of Cameroon. According to the Cameroon  
36  
37 National Institute of Statistics,[14] the four participating regions had a total population of 9.98  
38  
39 million in 2010 (51% of the country's total population: 19.41 millions). In this same year,  
40  
41 57.5% of the national population was aged 15 years and above, and about 52% resided in  
42  
43 what was defined as an urban area.[14] During three consecutive weeks leading to the  
44  
45 specified day of the survey, daily announcements were made through radio and television,  
46  
47 inviting all interested adults (or individuals aged 15 years and above) to report to any of the  
48  
49 screening sites in participating cities. Such explanation included advice on the importance of  
50  
51 measuring and knowing one's blood pressure under the slogan "I know my blood pressure.  
52  
53 And you?". Announcements were also made in churches and market places. The study  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 protocol was approved by the Cameroon National Ethics Committee and signed informed  
4  
5 consent obtained from each participant.  
6

### 7 *Data collection*

8  
9  
10 The screening was conducted by trained medical personnel, simultaneously in the four cities  
11  
12 on the specified date of May 17<sup>th</sup> 2011. All participants were subjected to a face-to-face  
13  
14 interview during which data were collected (using a standardized questionnaire) on  
15  
16 demographics, smoking habits and alcohol consumption, physical activity, parental history of  
17  
18 hypertension, personal medical history (where the diagnosis was made by a physician) of  
19  
20 hypertension including drug treatment, diabetes mellitus, gout and dyslipidemia. The  
21  
22 physical examination included blood pressure (BP) and anthropometric measurements. BP  
23  
24 (systolic and diastolic) was measured using a standardized protocol with the subject in a  
25  
26 seated position, and after at least 10 minutes rest. Subjects with evidence of recent (less than  
27  
28 30 minutes) alcohol intake or smoking were invited to a 30 minutes rest before BP  
29  
30 measurement. BP measurements were performed on the right arm using automated  
31  
32 sphygmomanometers (OMRON M3 HEM-7200-E Omron Matsusaka Co Ltd, Japan). Special  
33  
34 attention was given to the use of appropriate cuff sizes (13×23 cm or 16×30 cm). Weight (to  
35  
36 the nearest 0.5 kg) was measured with the use of an automated scale. Subjects were permitted  
37  
38 to keep on light clothing. Height (in meters to the nearest 0.5cm) was measured using a  
39  
40 wooden platform and a height rule. Body mass index (BMI in kg/m<sup>2</sup>) was calculated as  
41  
42 weight (kg)/[height (m) X height (m)]. Waist circumference was measured midway between  
43  
44 the iliac crest and the lower rib margin and the hip circumference was measured at the  
45  
46 intertrochanteric level. Waist-to-hip ratio (WHR) was calculated as waist (cm)/Hip (cm)  
47  
48 circumferences.  
49  
50  
51  
52  
53

### 54 *Definitions*



1  
2  
3 Respondents were classified as hypertensive if they had a systolic (and/or diastolic) BP of 140  
4 (90) mmHg or higher, or if they were on blood pressure lowering medications over the last 15  
5 consecutive days. Participants with hypertension were considered to be aware of their status if  
6 they answered 'yes' to the question 'have you ever been told by a doctor or health  
7 professional that you had hypertension?'. Treatment of high BP was defined by the use of BP  
8 lowering medications. Hypertension was considered to be controlled among treated  
9 individuals when systolic (and diastolic) SBP was < 140 (90) mmHg or <130 (80) mmHg in  
10 individuals with diabetes. Waist circumference >94 cm in men or 80 cm in women was  
11 considered to be high. Excessive alcohol consumption was based on intake of either more  
12 than three (two for women) standard glasses of wine per day or more than ten (five for  
13 women) local beers (1 local beer contains 28 g of alcohol) per week. Participants who smoked  
14 at least one cigarette per day or who had stopped smoking within the last three years were  
15 classified as current smokers, and those who had stopped smoking for more than three years  
16 were classified as former smokers. Regular non-work related physical activity was considered  
17 in participants reporting at least 30 min of intense physical activity, once a week or more.

### 18 ***Handling of participants with high blood pressure***

19 Participants with hypertension (known or screened-detected) received on-site medical  
20 counseling and were referred back to their attending physician (known cases), or to specialists  
21 within the vicinity of the participant's residential area for workup and long-term management.  
22 Few participants with excessively high BP with or without suspected acute target organ  
23 damage were immediately referred to emergency departments for appropriate care.

### 24 ***Statistical analysis***

25 Data analysis used the Statistical Package for Social Sciences (SPSS Inc, Chicago, IL) version  
26 17.0 software. Results are summarized as count and percentages for qualitative variables and  
27 mean and standard deviation (SD) for quantitative variables. Age-adjusted prevalence was

1  
2  
3 calculated using the Cameroon National population's age structure in 2010 as standard  
4  
5 population.[15] Direct standardization methods was applied.[16] Group comparisons used chi  
6  
7 square tests and equivalents for qualitative variables and Student t-test, analysis of the  
8  
9 variance (ANOVA) for quantitative variables. Logistic regressions analyses were used to  
10  
11 investigate potential determinants of prevalent hypertension and control. A p-value<0.05 was  
12  
13 used to characterize statistically significant results.  
14  
15

## 18 Results

### 20 *The study population*

21  
22 Two thousand one hundred and twenty eligible participants reported for screening in the four  
23  
24 regions including 649 (30.6%) in the Centre, 1167 (54.1%) in the Littoral and 304 (14.3%) in  
25  
26 the West and North West regions. Their overall profile including gender and region is  
27  
28 summarized in Table 1. Participants included 1003 women (47.3%). Compared with men,  
29  
30 women had similar age (43 vs. 44 years, p=0.19), similar waist circumference (93 vs. 93 cm,  
31  
32 p=0.80), and similar history of diabetes mellitus, dyslipidemia and gout (all p≥0.07, Table 1).  
33  
34 They were likely to have higher body mass index, higher prevalence of parental history of  
35  
36 hypertension, lower systolic and diastolic blood pressure, and were less likely to be either a  
37  
38 smoker or alcohol drinker and physically active (all p≤0.001, Table 1). With a few  
39  
40 exceptions, the above pattern was consistent within participating regions. However, the small  
41  
42 numbers of recruits in some subgroups translated into non-significant men/women differences  
43  
44 (Table 1). With the exception of smoking (p=0.07), differences were also apparent in the  
45  
46 baseline profile across Regions (all p≤0.01 for differences across regions).  
47  
48  
49  
50

### 51 *Blood pressure profile*

52  
53 Mean systolic and diastolic BP (SD) at the total population level (men vs. women) was 139  
54  
55 (25) vs. 134 (28) mmHg (p<0.001), and 83 (17) vs. 80 (17) mmHg (p=0.001). Mean systolic  
56  
57  
58  
59  
60

1  
2  
3 BP steadily increased with increasing age in men and women and across participating regions.  
4  
5 Diastolic BP also increased with increasing age, but only up to the fourth and fifth decade of  
6  
7 age, after which the pressure stabilized. This was observed in men and women and across  
8  
9 regions (Figure 1).  
10

11 The distribution of participants by BP categories according to the 2003 ESH/ESC  
12 classification[17] by sex overall and by age groups is provided in Table 2. An optimal BP was  
13  
14 observed in 21.6% of men and 29.6% of women. The prevalence of optimal or normal BP  
15  
16 decreased with increasing age in men and women (all  $p \leq 0.001$  for linear trend). Conversely,  
17  
18 with the exception of grade 1 hypertension (both  $p \geq 0.09$  for linearity) and high normal BP in  
19  
20 women only ( $p=0.13$ ), the prevalence of all other BP categories linearly increased with  
21  
22 increasing age (all  $p < 0.001$  for linear trend, Table 2).  
23  
24  
25  
26

### 27 ***Prevalence of hypertension, and awareness and control rates***

28  
29 The prevalence of hypertension was 47.5% overall, and 50.1% and 44.6% in men and women  
30  
31 respectively ( $p < 0.001$ ), Table 3. As expected, prevalence rate sharply increased with age  
32  
33 down from 31.7% (men) and 20.2% (women) in the age group <35 years, up to 77.6% (men)  
34  
35 and 75.2% (women) in the age group 55 years and above (Table 3). Awareness rate increased  
36  
37 with increasing age in men and women (both  $p < 0.001$  for linear trend). Among participants  
38  
39 with hypertension, 24.6% in men and 40.5% in women were aware of their condition, and  
40  
41 those remaining were newly diagnosed. Of those aware of their hypertensive status, 57.9% in  
42  
43 men and 61.3% in women were on BP lowering medications, similarly across age groups in  
44  
45 men ( $p=0.53$  for linear trend), and with a modest linearly increasing trend with age in women  
46  
47 ( $p=0.03$ , Table 3). Among treated patients, 27.5% in men and 38.7% in women were at target  
48  
49 BP levels [i.e. systolic (and diastolic) BP <140 (90) mmHg], and similarly across age strata  
50  
51 (both  $p \geq 0.06$  for linear trend). Control rate was about 10% lower when the target BP level of  
52  
53 <130 (80) was applied to participants with diabetes (Table 3).  
54  
55  
56  
57  
58  
59  
60

### *Predictors of hypertension and control among urban dwellers*

In unadjusted logistic regressions analysis, male gender, increasing age, Region, parental history of hypertension, personal history of diabetes, gout, excessive alcohol consumption, high BMI and high waist circumference were associated with prevalent hypertension (Table 4). In multivariable adjusted models, history of gout and excessive alcohol consumption were no longer associated with prevalent hypertension. Table 5 shows the crude and adjusted odds ratios (ORs) of hypertension control among treated patients. Male sex, high BMI and physical inactivity were associated with poor control of hypertension, while being from Regions other than Centre or Littoral was associated with good control (Table 5).

### *Hypertension control according to the number of risk factors*

Hypertension control was assessed according to the clustering of cardiovascular risk factors including current or past smoking, self-reported diabetes, self-reported dyslipidemia, overweight or obesity, high waist and physical inactivity. Among 116 participants with none of the above, no case of hypertension was recorded. The proportion of patients at target BP levels among those treated steadily declined from 58.3% among those with only one risk factor to 11.8% among those with four or more risk factors (Figure 2). The declining trend was linear ( $p < 0.001$  for linear trend). In logistic regression models adjusted for sex, age and region, each additional cardiovascular risk factor from zero to four or more, reduced the chances of being at target BP levels by 70% (95% confidence interval: 49-82%). The range of effect was similar in men and women [OR (95% CI): 0.32 (0.14-0.71) in men and 0.30 (0.14-0.63) in women] with no evidence of significant statistical interaction ( $p = 0.17$  for interaction).

### **Discussion**

In this self-selected urban adult population study from Cameroon, we found a high prevalence of hypertension, coupled with low detection, treatment and control rates. The high

1  
2  
3 prevalence was largely driven by age, as well as by gender and excess weight. However,  
4  
5 among those diagnosed and on treatment, control rate was similar across age groups, although  
6  
7 there were suggestions of regional differences, possibly reflecting underlying differences in the  
8  
9 access to healthcare and health resources utilization. The coincidence of cardiovascular risk  
10  
11 factors in the same individual was associated with poor blood pressure control among treated  
12  
13 participants. Our findings update previous reports on hypertension in Cameroon and provide  
14  
15 comparative data across major cities in the country.  
16  
17

### 18 *Prevalence of hypertension*

20 During the last ten years, at least two prevalence studies on hypertension have been reported  
21  
22 in urban Cameroon, applying similar definitions for hypertension, but different sampling  
23  
24 strategies.[7 9 18] The age-adjusted prevalence of hypertension in the current study is higher  
25  
26 than that reported by Kamadjeu[9] in 2003, but similar to the findings of Fezeu[7] around that  
27  
28 same time. This balance of findings would tend to suggest that the prevalence of hypertension  
29  
30 in this setting is either stabilizing or growing at a much slower pace than previously  
31  
32 reported.[7]  
33  
34

36 Elsewhere, available data on hypertension in Africa are from very heterogeneous studies, and  
37  
38 therefore offer less opportunities for reliable comparison.[3] Such heterogeneities include  
39  
40 differences in sampling methods and study settings (predominance of hospital based study),  
41  
42 the type of subjects enrolled, the measurements of blood pressure and definition of  
43  
44 hypertension, and the time period when the study was conducted.[19] Reliable, large-scale,  
45  
46 population-based data on high blood pressure in sub-Saharan Africa are very limited; however  
47  
48 available recent studies provide findings that demonstrate similarly high prevalence of  
49  
50 hypertension in urban settings.[20-22] Moreover, those findings already tend to be similar to  
51  
52 those reported in the developed world,[23 24] therefore, raising serious concerns given the  
53  
54 young age of clinical onset of hypertension in Africa.  
55  
56  
57  
58  
59  
60

### *Awareness, treatment and control of hypertension*

In Cameroon, over the last ten years, there have been a number of initiatives aimed at scaling up the fight against chronic diseases in general, and hypertension and diabetes mellitus in particular,[25] including: 1) the adoption of a National Strategy for hypertension and diabetes,[25] and 2) the development of training and task-shifting programmes to improve detection and management at primary care level.[13 26] Findings from our study tend to suggest that the good will contained in the National Strategy has not yet been fully translated into actions with sizable positive effects on the health of the population. For instance, the Strategy aimed to improve level of risk factors by 25% and achieve optimal control among those diagnosed with the condition.[25] However, we found awareness, treatment and control rates which were within the range of those previous reported in Cameroon prior to the adoption of the Strategy[7 9] and recently in other settings in Africa.[20 22 25] The low awareness rate could be blamed on low detection activity and accordingly non-optimal performance of the National strategy. It is also possible that many participants already diagnosed with hypertension, and perhaps on treatment and controlled on such treatment, did not feel the need to attend the screening campaign again. This would have the undesirable effect of biasing our estimates by providing much lower than the true figures. It is also possible that those with known and treated condition instead turned out in higher number to use the campaign as an opportunity for their health checkup free of charge. In general however, low awareness of hypertension has been reported as a global phenomenon,[27] although the magnitude may be less important in the developed world[23 28]. In the USA for instance, awareness of hypertension is as higher as 76%,[28] reflecting the success achieved by a coordinated policy to detect individuals with higher-than-optimal blood pressure levels. The low treatment and control rates in our study reflect the interplay between many factors which were not directly captured by the current study. These include both patient-level,

1  
2  
3 healthcare provider level and health system level factors. Indeed, patients are expected to be  
4  
5 treated and controlled only if they can access appropriate health services, receive adequate  
6  
7 advice and prescriptions, and subsequently afford and adhere to those prescriptions.  
8

9  
10 Accessibility to health care facility has likely improved in urban settings in Cameroon in  
11  
12 recent years. However the physician-to-population ratio, just like in many other countries in  
13  
14 the region, is still very low[29] and may explain the low awareness and treatment gaps.

15  
16 Affordability of the cost of care also remains a major barrier in the study setting where out-of-  
17  
18 pocket spending is the main source of funding for healthcare costs. Adherence to prescribed  
19  
20 medications is another patient-level determinant of risk factor control not investigated in the  
21  
22 present study. Studies in Africa have shown that non-adherence to treatment and follow-up  
23  
24 for hypertension was very common.[30-32] In one intervention study in Cameroon for  
25  
26 instance, just about half of participants were still in the programme at 1-year of follow-up.[31]  
27  
28

### 29 ***Potential limitations and strengths of our study***

30  
31 The present study has some limitations. Participants were self-selected and may therefore not  
32  
33 necessarily be representative of the general population in participating cities. Access to mass  
34  
35 media (radio and television) is almost universal in major cities in the countries, and there is  
36  
37 therefore no suggestion that advertisement of the campaign would have selectively reached  
38  
39 certain portions of the population. It remains however; that participants in the study could still  
40  
41 differ from the general population by being more or less health conscious, and having less  
42  
43 severe disease for example, which could affect some parameters in the study. The study used  
44  
45 a cross-sectional design, which precludes any causality inference. Diagnosis of hypertension  
46  
47 was based on blood pressure measurements during a single encounter, which is at variant with  
48  
49 guidelines recommendations for hypertension diagnosis using two measurements recorded on  
50  
51 three separate occasions.[17] This may have overestimated the prevalence of hypertension  
52  
53 and underestimated the level of blood pressure control. This however, would not affect  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 comparisons with previous epidemiological studies that have used similar measurement  
4 methodology. The strengths of this study include the large sample of the general population  
5 and, the rigorous collection of various lifestyle factors, medical data and blood pressure  
6 measurements by trained staff according to standardized protocols, the adequate  
7 standardization of prevalence and allowing comparisons with other African countries. In  
8 addition, our sampling approach provides evidence that simple announcements through mass  
9 media can attract from the community a large number of individual at risk of undiagnosed  
10 hypertension.

### 21 **Conclusions**

22 In conclusion, our study confirms the high prevalence of hypertension previously reported in  
23 urban settings in Africa. Detection, treatment and control efforts are still well below optimal.  
24 This raises serious concerns about the prospects of having to care very soon for both patients  
25 with higher-than-optimal blood pressure and many more with target organ lesions subsequent  
26 to longstanding hypertension. There are already some indications that the burden of stroke,  
27 end-stage renal disease and heart failure related to hypertension is growing in the country and  
28 the region.[2 6 33]

### 38 **Perspectives**

39 The low awareness, treatment and control rates of hypertension in this potentially health  
40 conscious urban sub-Saharan population invite innovative approaches to improve prevention,  
41 detection, treatment of hypertension beyond the traditional healthcare facilities based  
42 approaches which are currently in force in many countries in the region.

54 **Declaration of competing interest.** None for all authors.



1  
2  
3 **Author contribution.** Dzudie and Kengne had full access to all of the data in the study and  
4 takes responsibility for the integrity of the data and the accuracy of the data analysis.  
5  
6

7  
8 Study concept and design: Dzudie, Kengne, Muna, Ngu, Kingue.  
9

10  
11 Acquisition of data: Ba, Menanga, Kouam Kouam, Abah, Monkam, Biholong, Mintom,  
12  
13 Kamdem, Djomou, Njebet, Ouambo, Luma,  
14

15  
16 Analysis and interpretation: Dzudie, Kengne, Muna  
17

18  
19 Drafting of the manuscript: Dzudie, Kengne, Muna  
20

21  
22 Critical revision of the manuscript for important intellectual content: all co-authors  
23  
24  
25  
26  
27

## 28 **Acknowledgements**

29  
30 The authors would like to express their gratitude to the following bodies and individuals for  
31 their contribution to the success of this study: 1) The Cameroon Ministry of public health for  
32 providing the blood pressure devices and health staff; 2) The executive committee and  
33 members of the Cameroon Cardiac Society for their support for data collection; 3) Servier  
34 Pharma Cameroon for a financial contribution to support data processing and drafting of the  
35 manuscript; 4) All specialist physicians, enthusiastic general practitioners, medical students  
36 and nurses involved in data collection; and 5) All those who helped at the different stages of  
37 the project and the fellow Cameroonians who volunteered across the four participating cities  
38 to take part in the study.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 **Data sharing statement:** No additional data available  
52

## 53 **Appendix 1**

54  
55  
56 Cameroon Cardiac Society (CCS) investigators group:  
57  
58  
59  
60

- 1  
2  
3 (1) Douala: Anastase Dzudie, Hamadou Ba, Henri Roger Ngote, Christian Biholong,  
4 Félicité Kamdem, Armel Djomou, Jules Njebet, Cyrille Ouambo, Roger Mboulley  
5 Kotto, Barbara Bouellet Abeng, Marielle Epacka Ewane Lobe and Yves Monkam.  
6  
7  
8  
9  
10 (2) Yaounde : Alain Menanga, Pierre Mintom, Euloge Yiagnigni, MÉRIMÉE Ouankou,  
11 Christophe Nouedoui, Pierre Ndobu, Marie Ntep, Monique Kenfack, Sylvie Ndongu,  
12 Martine Tchuem, Edvine Wawo, Walinjom F.T. Muna, Katleen Ngu Blackett and  
13 Samuel Kingue.  
14  
15  
16  
17  
18 (3) Bafoussam: Charles Kouam Kouam  
19  
20  
21 (4) Bamenda: Joseph Abah.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

### 33 References

- 34  
35  
36 1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of  
37 worldwide data. *Lancet* 2005;365:217-23.  
38  
39  
40 2. Kengne AP, Anderson CS. The neglected burden of stroke in Sub-Saharan Africa. *Int J*  
41 *Stroke* 2006;1:180-90.  
42  
43  
44 3. Addo J, Smeeth L, Leon DA. Hypertension in sub-saharan Africa: a systematic review.  
45 *Hypertension* 2007;50:1012-8.  
46  
47  
48 4. Kengne AP, Amoah AG, Mbanya JC. Cardiovascular complications of diabetes mellitus in  
49 sub-Saharan Africa. *Circulation* 2005;112:3592-601.  
50  
51  
52 5. Damasceno A, Cotter G, Dzudie A, et al. Heart failure in sub-saharan Africa: time for  
53 action. *J Am Coll Cardiol* 2007;50:1688-93.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 6. Kengne AP, Awah PK. Classical cardiovascular risk factors and all-cause mortality in rural  
4  
5 Cameroon. *Qjm* 2009;doi:10.1093/qjmed/hcn175.  
6
- 7 7. Fezeu L, Kengne AP, Balkau B, et al. Ten-year change in blood pressure levels and  
8  
9 prevalence of hypertension in urban and rural Cameroon. *J Epidemiol Community*  
10  
11 *Health* 2010;64:360-5.  
12
- 13 8. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular  
14  
15 events: results of prospectively-designed overviews of randomised trials. *Lancet*  
16  
17 2003;362:1527-35.  
18
- 19 9. Kamadjeu RM, Edwards R, Atanga JS, et al. Prevalence, awareness and management of  
20  
21 hypertension in Cameroon: findings of the 2003 Cameroon Burden of Diabetes  
22  
23 Baseline Survey. *J Hum Hypertens* 2006;20:91-2.  
24  
25
- 26 10. Leon DA. Cities, urbanization and health. *Int J Epidemiol* 2008;37:4-8.  
27
- 28 11. Popkin BM. Global nutrition dynamics: the world is shifting rapidly toward a diet linked  
29  
30 with noncommunicable diseases. *Am J Clin Nutr* 2006;84:289-98.  
31  
32
- 33 12. de-Graft Aikins A, Unwin N, Agyemang C, et al. Tackling Africa's chronic disease  
34  
35 burden: from the local to the global. *Globalization and health* 2010;6:5.  
36  
37
- 38 13. Lekoubou A, Awah P, Fezeu L, et al. Hypertension, diabetes mellitus and task shifting in  
39  
40 their management in sub-Saharan Africa. *Int J Environ Res Public Health* 2010;7:353-  
41  
42 63.  
43  
44
- 45 14. Cameroon's National Institute of Statistics. Statistical Yearbook 2010, 2011:39-52.  
46
- 47 15. Cameroon's National Institute of Statistics. Population du Cameroun en 2010, 2011.  
48
- 49 16. Woodward M, editor. *Epidemiology: study design and data analysis*. Second ed. New  
50  
51 York: Chapman & Hall/CRC, 2005.  
52
- 53 17. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of  
54  
55 Arterial Hypertension: The Task Force for the Management of Arterial Hypertension  
56  
57

- 1  
2  
3 of the European Society of Hypertension (ESH) and of the European Society of  
4  
5 Cardiology (ESC). *J Hypertens* 2007;25:1105-87.  
6  
7 18. Kengne AP, Awah KP, Fezeu L, et al. The burden of high blood pressure and related risk  
8  
9 factors in urban sub-Saharan Africa: Evidences from Douala in Cameroon. *African*  
10  
11 *Health Sciences* 2007;7:38-44.  
12  
13 19. Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic  
14  
15 blood pressure since 1980: systematic analysis of health examination surveys and  
16  
17 epidemiological studies with 786 country-years and 5.4 million participants. *Lancet*  
18  
19 2011;377:568-77.  
20  
21  
22 20. Jenson A, Omar AL, Omar MA, et al. Assessment of hypertension control in a district of  
23  
24 Mombasa, Kenya. *Glob Public Health* 2011;6:293-306.  
25  
26  
27 21. Ulasi, II, Ijoma CK, Onodugo OD. A community-based study of hypertension and cardio-  
28  
29 metabolic syndrome in semi-urban and rural communities in Nigeria. *BMC Health*  
30  
31 *Serv Res* 2010;10:71.  
32  
33  
34 22. Damasceno A, Azevedo A, Silva-Matos C, et al. Hypertension prevalence, awareness,  
35  
36 treatment, and control in mozambique: urban/rural gap during epidemiological  
37  
38 transition. *Hypertension* 2009;54:77-83.  
39  
40  
41 23. Wagner A, Sadoun A, Dallongeville J, et al. High blood pressure prevalence and control  
42  
43 in a middle-aged French population and their associated factors: the MONA LISA  
44  
45 study. *J Hypertens* 2011;29:43-50.  
46  
47  
48 24. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood  
49  
50 pressure levels in 6 European countries, Canada, and the United States. *Jama*  
51  
52 2003;289:2363-9.  
53  
54 25. Njamnshi AK, Bella Hiag A, Mbanya JC. From research to policy: the development of a  
55  
56 national diabetes programme in Cameroon. *Diabetes Voice* 2006;55:18-21.  
57  
58  
59  
60

- 1  
2  
3 26. Kengne AP, Sobngwi E, Fezeu L, et al. Setting-up nurse-led pilot clinics for the  
4  
5 management of non-communicable diseases at primary health care level in resource-  
6  
7 limited settings of Africa *PAMJ* 2009;3:10.  
8  
9  
10 27. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the  
11  
12 community: is the 'rule of halves' still valid? *J Hum Hypertens* 1997;11:213-20.  
13  
14 28. Cheung BM, Ong KL, Man YB, et al. Prevalence, awareness, treatment, and control of  
15  
16 hypertension: United States National Health and Nutrition Examination Survey 2001-  
17  
18 2002. *J Clin Hypertens (Greenwich)* 2006;8:93-8.  
19  
20  
21 29. World Health Organisation. Task shifting to tackle health worker shortage. Geneva, 2007.  
22  
23 30. Kengne AP, Awah PK, Fezeu LL, et al. Primary health care for hypertension by nurses in  
24  
25 rural and urban sub-Saharan Africa. *J Clin Hypertens (Greenwich)* 2009;11:564-72.  
26  
27  
28 31. Labhardt ND, Balo JR, Ndam M, et al. Improved retention rates with low-cost  
29  
30 interventions in hypertension and diabetes management in a rural African environment  
31  
32 of nurse-led care: a cluster-randomised trial. *Trop Med Int Health* 2011.  
33  
34 32. Dennison CR, Peer N, Steyn K, et al. Determinants of hypertension care and control  
35  
36 among peri-urban Black South Africans: the HiHi study. *Ethn Dis* 2007;17:484-91.  
37  
38 33. Halle MP, Kengne AP, Ashuntantang G. Referral of patients with kidney impairment for  
39  
40 specialist care in a developing country of sub-Saharan Africa. *Ren Fail* 2009;31:341-8.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Legend for figures and tables**  
4

5  
6 **Figure 1:** Mean systolic and diastolic blood pressure by age groups for men (left panel) and  
7  
8 women (right panel).  
9

10  
11 **Figure 2** – Blood pressure control among participants with hypertension according to the  
12  
13 number of cardiovascular risk factors.  
14

15  
16  
17 Risk factors considered were: overweight or obesity, high waist, current or past smoking,  
18  
19 physical inactivity, diagnosed diabetes, dyslipidemia. None of the 116 participants with none  
20  
21 of the risk factor had hypertension.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1 - General characteristics of the study population overall and by Region**

Characteristic	Regions									Overall			
	Centre			Littoral			North-West and West			p region	Men	Women	p
	Men	Women	P	Men	Women	P	Men	Women	p				
N	376	273		609	558		132	172		<0.001	1117	1003	
Mean age, yrs. (SD)	41 (12)	42 (14)	0.43	45 (13)	43 (14)	0.33	48 (14)	45 (14)	0.08	<0.001	44 (13)	43 (14)	0.19
Age groups, n			0.26			0.006			0.22	<0.001			0.01
<35 years	134	97		145	180		23	44			302	321	
35-44 years	99	57		154	108		32	40			285	205	
45-54 years	86	65		163	139		34	47			284	251	
≥55 years	57	54		146	131		43	41			246	226	
Mean BMI, kg/m <sup>2</sup> (SD)	26.2 (4.0)	27.2 (4.5)	0.002	26.9 (4.8)	29.0 (6.3)	<0.001	27.6 (5.0)	29.3 (5.4)	0.006	<0.001	26.7 (4.6)	28.6 (5.8)	<0.001
Waist girth, cm (SD)	96 (13)	94 (12)	0.04	91 (13)	91 (15)	0.31	95 (12)	97 (12)	0.15	<0.001	93 (13)	93 (14)	0.80
Mean SBP, mmHg (SD)	133 (22)	129 (24)	0.06	142 (26)	139 (30)	0.05	136 (25)	125 (25)	<0.001	<0.001	139 (25)	134 (28)	<0.001
Mean DBP, mmHg (SD)	77 (17)	77 (16)	0.98	85 (17)	82 (18)	0.001	85 (15)	79 (15)	0.001	<0.001	83 (17)	80 (17)	0.001
Parental hypertension, n	77	77	0.02	158	191	0.002	38	55	0.62	0.01	273	323	<0.001
History of diabetes, n	27	27	0.22	27	31	0.42	21	31	0.65	<0.001	75	89	0.07
History of dyslipidemia, n	1	0	>0.99	4	9	0.16	0	0	N/A	0.005	5	9	0.28
History of gout, n	0	1	0.42	13	9	0.53	1	0	0.43	<0.001	14	10	0.68
Physical activity, n	160	86	0.004	334	180	<0.001	82	104	0.77	<0.001	576	370	<0.001
Smoking, n			<0.001			<0.001			<0.001	0.07			<0.001
Never	320	267		500	540		113	170			933	977	
Former	21	26		43	7		4	0			68	12	
Current	35	36		66	11		15	2			116	14	
Excessive alcohol, n	85	17	<0.001	147	51	<0.001	51	32	<0.001	<0.001	283	100	<0.001

BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; SD, standard deviation

**Table 2 - Prevalence of Blood Pressure categories by sex and age group among self-selected urban dwellers in Cameroon**

Gender	Variable	Overall	Overall*	Age groups				P-trend
				<35 years	35-44 years	45-54 years	≥55 years	
Men	Isolated systolic hypertension (%)	19.1	16.6 (15.1-18.1)	4.7	2.9	4.9	6.5	<0.001
	Optimal blood pressure (%)	21.6	23.1 (21.6-24.6)	8.0	7.3	3.9	2.3	<0.001
	Normal blood pressure (%)	19.8	19.8 (18.3-21.3)	6.7	5.4	5.5	2.2	<0.001
	High normal blood pressure (%)	16.7	17.6 (16.1-19.1)	6.2	4.6	3.5	2.3	<0.001
	Grade 1 hypertension (%)	12.4	9.7 (8.2-11.2)	2.5	3.1	3.9	2.8	0.09
	Grade 2 hypertension (%)	11.7	8.0 (6.5-9.5)	1.5	2.8	3.5	4.0	<0.001
	Grade 3 hypertension (%)	9.6	5.2 (3.7-6.7)	0.4	2.0	2.8	4.4	<0.001
Women	Isolated systolic hypertension (%)	13.3	10.9 (9.4-12.4)	2.7	2.2	2.8	5.6	<0.001
	Optimal blood pressure (%)	29.6	38.0 (36.5-39.5)	15.3	6.0	5.2	3.1	<0.001
	Normal blood pressure (%)	17.4	19.0 (17.5-20.5)	6.6	4.6	3.8	2.4	0.001
	High normal blood pressure (%)	13.9	13.0 (11.5-14.5)	3.8	3.1	3.7	3.3	0.34
	Grade 1 hypertension (%)	9.9	8.3 (6.8-11.8)	2.0	2.6	3.2	2.1	0.13
	Grade 2 hypertension (%)	8.1	6.0 (4.5-7.5)	1.3	0.7	2.9	3.5	<0.001
	Grade 3 hypertension (%)	8.1	5.8 (4.3-7.3)	0.4	1.3	2.8	5.6	<0.001

\* Age standardized according to the 2010 Cameroon national population distribution.



**Table 3 - Hypertension prevalence, awareness and control among self-selected urban dwellers in Cameroon**

Gender	Variable	Overall	Overall*	Age groups				P-trend
				<35 years	35-44 years	45-54 years	≥55 years	
Men	Prevalence (%)	50.1	41.3 (39.8-42.8)	31.7	38.9	57.2	77.6	<0.001
	SBP≥140 or DBP≥90 mmHg or treatment (n)	560	560	96	111	162	191	
	Awareness (%)	24.6	13.5 (8.9-18.1)	6.3	12.6	21.6	43.5	<0.001
	Among hypertensives (n)	138	138	6	14	35	83	
	Treatment (%)	57.9	54.6 (-17.6 to 126.8)	50	64.2	65.7	54.2	0.53
	Among aware hypertensives	80	80	3	9	23	45	
	Control A (%)	18.8	28.2 (-115.9 to 172.3)	33.3	22.2	21.7	15.5	0.37
	Among treated hypertensive (n)	15	15	1	2	5	7	
	Control B (%)	27.5	50.3 (-93.8 to 14.4)	66.6	22.2	26.1	26.7	0.50
	Among treated hypertensive (n)	22	22	2	2	6	12	
Women	Prevalence (%)	44.6	32.5 (31.0-34.0)	20.2	35.6	55.8	75.2	<0.001
	SBP≥140 or DBP≥90 mmHg or treatment (n)	447	447	64	73	140	170	
	Awareness (%)	40.5	20.9 (13.8-28.0)	9.3	26.0	42.8	54.5	<0.001
	Among hypertensives (n)	181	181	6	19	60	96	
	Treatment (%)	61.3	43.3 (-30.4 to 117.0)	33.3	57.9	53.3	68.9	0.03
	Among aware hypertensives	111	111	2	11	32	66	
	Control A (%)	28.8	8.0 (-212.6 to 228.6)	0	18.1	21.8	34.8	0.27
	Among treated hypertensive (n)	32	32	0	2	7	23	
	Control B (%)	38.7	12.8 (-207.8 to 233.4)	0	2.7	31.3	45.5	0.06
	Among treated hypertensive (n)	43	43	0	3	10	30	

Data are percentages with numerators below. Control A, blood pressure below 140/90 mmHg or 130/80 mmHg among diabetic patients; Control B, blood pressure below 140/90 mmHg among all subjects. DBP, diastolic blood pressure; SBP, systolic blood pressure.

\* Age standardized according to the 2010 Cameroon national population distribution.

**Table 4 - Crude and adjusted odds ratios for predictors of hypertension among self-selected urban dwellers in Cameroon.**

Variable	Category	Unadjusted odd ratios (95% CI)	p	Adjusted odd ratios (95% CI)*	p
Sex	Men	1.25 (1.05-1.48)	0.01	1.63 (1.34-2.00)	<0.001
Age	<35 years	1 (reference)	<0.001	1 (Reference)	<0.001
	35-44 yrs	1.74 (1.35-2.25)		1.32 (1.01-1.73)	
	45-54 yrs	3.75 (2.93-4.81)		2.81 (2.16-3.64)	
	≥55 yrs	9.41 (7.12-12.43)		8.27 (6.19-11.04)	
Region	Centre	1 (Reference)	<0.001	1 (Reference)	<0.001
	Littoral	2.11 (1.73-2.57)		1.89 (1.52-2.36)	
	Others	1.80 (1.36-2.37)		1.38 (1.01-1.89)	
Parental hypertension	Yes	1.47 (1.21-1.77)	<0.001	1.55(1.25-1.92)	<0.001
Diabetes mellitus	Yes	3.77 (2.61-5.44)	<0.001	2.63 (1.75-3.94)	<0.001
Dyslipidemia	Yes	2.00 (0.67-5.98)	0.22	1.55 (0.47-5.11)	0.47
Gout	Yes	3.36 (1.33-8.49)	0.01	1.70 (0.62-4.67)	0.30
Smoking	Never	1 (Reference)	0.11	1 (Reference)	0.62
	Former	1.59 (1.01-2.51)		0.96 (0.59-1.65)	
	Current	0.90 (0.63-1.29)		0.82 (0.54-1.22)	
Physical activity	No	0.90 (0.76-1.07)	0.23	1.13 (0.93-1.38)	0.21
Excessive alcohol	Yes	1.33 (1.06-1.66)	0.01	1.05 (0.81-1.36)	0.70
Body mass index	Normal	1 (Reference)	<0.001	1 (Reference)	<0.001
	Overweight	2.03 (1.65-2.50)		1.94 (1.54-2.45)	
	Obese	3.54 (2.83-4.43)		3.32 (2.57-4.29)	
High waist girth		2.12 (1.78-2.52)	<0.001	1.94 (1.51-2.48)	<0.001

\* age, sex, parental history of hypertension, body mass index and region adjusted; CI, confidence interval

**Table 5 - Crude and adjusted odds ratios for predictors of hypertension control among self-selected and treated hypertensives in four main cities of Cameroon.**

Variable	Category (%)	Unadjusted odd ratios (95% CI)	P	Adjusted odd ratios (95% CI)*	p
Sex	Men	0.59 (0.35-1.00)	0.05	0.47 (0.26-0.86)	0.01
Age	<35 years	1.00 (Reference)	0.87	1.00 (Reference)	0.63
	35-44 yrs	0.54 (0.12-2.32)		0.38 (0.07-1.99)	
	45-54 yrs	0.68 (0.19-2.45)		0.57 (0.13-2.41)	
	≥55 yrs	0.67 (0.19-2.34)		0.46 (0.11-1.88)	
Region	Centre	1.00 (Reference)	<0.001	1.00 (Reference)	<0.001
	Littoral	0.72 (0.35-1.50)		0.70 (0.33-1.52)	
	Others	3.36 (1.64-6.87)		3.50 (1.65-7.42)	
Parental hypertension	Yes	1.44 (0.87-2.40)	0.16	1.56 (0.89-2.75)	
Diabetes mellitus	Yes	2.73 (1.60-4.67)	<0.001	1.83 (0.98-3.39)	0.06
Dyslipidemia	Yes	0.74 (0.08-6.75)	0.79	1.30 (0.13-13.26)	0.83
Gout	Yes	NA (None)			
Smoking	Never	1.00 (Reference)	0.53	1.00 (Reference)	0.72
	Former	0.79 (0.21-2.89)		1.26 (0.30-5.34)	
	Current	0.32 (0.04-2.57)		0.44 (0.05-3.97)	
Physical activity	No	0.30 (0.17-0.56)	<0.001	0.36 (0.20-0.66)	0.001
	Excessive	0.59 (0.26-1.32)		0.64 (0.26-1.60)	
Body mass index	Normal	1.00 (Reference)	0.002	1.00 (Reference)	0.003
	Overweight	0.41 (0.22-0.77)		0.44 (0.22-0.90)	
	Obese	0.34 (0.18-0.66)		0.28 (0.14-0.59)	
High waist girth		0.86 (0.51-1.44)	0.56	0.77 (0.33-1.77)	0.54

\* age, sex, parental history of hypertension, body mass index and region adjusted; CI, confidence interval.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Figure 1:





Figure 2



**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any pre-specified hypotheses	5-6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6-8
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	7-8
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	8-9
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	8-9

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	9
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	9-10
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	11
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14-15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-14
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).



**Prevalence, awareness, treatment and control of hypertension in a self-selected sub-Saharan African urban population: A cross-sectional study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001217.R1
Article Type:	Research
Date Submitted by the Author:	02-Jul-2012
Complete List of Authors:	Dzudie, Anastase Kengne, Andre; South African Medical Research Council, National Collaborative Programme on Cardiovascular and metabolic Disease; The George Institute for Global Health, Muna, Walinjom Ba, Hamadou Menanga, Alain Kouam Kouam, Charles Abah, Joseph Monkam, Yves; General Hospital of Douala, Department of Internal Medicine Biholong, Christian; General Hospital of Douala, Department of Internal Medicine Mintom, Pierre Kamdem, Felicite; General Hospital of Douala, Department of Internal Medicine Djomou, Armel; General Hospital of Douala, Department of Internal Medicine Ndjebet, Jules; General Hospital of Douala, Department of Internal Medicine Ouambo, Cyrille Luma, Henry; General Hospital of Douala, Department of Internal Medicine Ngu, Kathleen Kingue, Samuel
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine, Epidemiology
Keywords:	Hypertension < CARDIOLOGY, EPIDEMIOLOGY, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts



1  
2  
3 **Prevalence, awareness, treatment and control of hypertension in a self-selected sub-**  
4  
5 **Saharan African urban population: A cross-sectional study**  
6  
7

8 **Short title:** Awareness, treatment and control of hypertension  
9

10 Anastase Dzudie, MD, FESC(1); André Pascal Kengne, MD, PhD(2); Walinjom F.T. Muna, MD,  
11 PhD, FACC(3); Hamadou Ba, MD(1); Alain Menanga, MD (4); Charles Kouam Kouam' MD(5);  
12 Joseph Abah, MD(6); Yves Monkam, MD(1); Christian Biholong, MD(1); Pierre Mintom' MD(4);  
13 Félicité Kamdem, MD(1); Armel Djomou, MD(1); Jules Ndjebet, MD(1); Cyrille Ouambo, MD,  
14 PhD(1); Henri Luma, MD(1), Katleen Blackett Ngu, MD, FESC(6); Samuel Kingue, MD(6); On  
15 behalf of the CCS investigator group\*.  
16  
17  
18  
19  
20  
21

22 (1) Department of Internal Medicine, Douala General Hospital and Buea Faculty of medicine,  
23 Cameroon  
24  
25

26 (2) NCRP or Cardiovascular and metabolic disease, South African Medical Research Council &  
27 University of Cape Town, Cape Town, South Africa  
28  
29

30 (3) Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, Yaounde,  
31 Cameroon  
32  
33

34 (4) Department of Internal Medicine, Yaounde General Hospital , Cameroon  
35  
36

37 (5) Department of Internal Medicine, Bafoussam Regional Hospital , Cameroon  
38  
39

40 (6) Department of Internal Medicine, Bamenda Military Hospital , North West Region, Cameroon  
41

42 **Correspondence to:** Dr Anastase Dzudie, MD; FESC. Douala General Hospital; PO Box 4856,  
43 Douala General Hospital, Douala – Cameroon, Tel: +(237)79617981; Fax: +(237)33370146; email:  
44 [aitdzudie@yahoo.com](mailto:aitdzudie@yahoo.com)  
45  
46  
47

48 Tables #4; Figures #1.  
49

50 Word count: Abstract (265); Main text excluding reference, figure legend and references (3720)  
51  
52  
53

54 \* Members list in the appendix section  
55  
56  
57  
58  
59  
60

## Abstract

**Objectives.** Hypertension has been established as a major public health problem in Africa, but its specific contributions to disease burden are still incompletely understood. We quantified the burden and determinants of hypertension, detection, treatment and control rates among adults in major cities in Cameroon.

**Design.** Cross-sectional study

**Settings.** Community-based multicenter study in major cities in Cameroon

**Participants.** Participants were self-selected urban dwellers from the Center, Littoral, North-West and West Regions, who attended on May 17th 2011 a screening campaign advertised through mass media.

**Primary and secondary outcomes measures.** Hypertension defined as systolic (and/or diastolic) blood pressure  $\geq 140$  (90) mmHg, or ongoing blood pressure (BP) lowering medications.

**Results.** In all, 2120 participants (1003 women) were included. Among them, 1007 (prevalence rate 47.5%) had hypertension, including 319 (awareness rate 31.7%) who were aware of their status. The prevalence of hypertension increased with age overall and by sex and region. Among aware hypertensive participants, 191 (treatment rate 59.9%) were on regular BP lowering medication, and among those treated, 47 (controlled rate 24.6%) were at target BP levels (i.e. systolic (and diastolic) BP  $<140$  (90) mmHg). In multivariable logistic regressions analysis, male gender, advanced age, parental history of hypertension, diabetes mellitus, elevated waist, and elevated body mass index (BMI) were the significant predictors of hypertension. Likewise, male gender, high BMI and physical inactivity were associated with poor control.

**Conclusions.** High prevalence of hypertension with low awareness, treatment and control were found in this urban population; these findings are significant and alarming with

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

consideration to the various improvements in the access to healthcare and the continuing efforts to educate communities over the past decades.

Word count - 265

**Key Words:** Hypertension, prevalence, awareness, treatment, control, Cameroon, Africa

For peer review only

## Article summary

### Article focus

- This article quantified the burden and determinants of hypertension, detection, treatment and control rates among self-selected adults in major cities in Cameroon, central Africa

### Key messages

- The prevalence of hypertension was very high in this population, coupled with low detection, treatment and control rates.
- Age, gender and excess weight were the main drivers of the high prevalence, while the coincidence of classical cardiovascular risk factors was associated with poor control.

### Strengths and limitations of this study

- Major strengths of this study include the large sample, the multicenter nature, the rigorous data collection on a range of determinants and provision of standardized prevalence figures.
- Limitations include the selection of participants, and hypertension diagnosis based on blood pressure measurement during a single encounter.

## Introduction

Hypertension has been established as a major public health problem worldwide.[1] Several published studies suggest that hypertension is the commonest modifiable risk factor for stroke, congestive heart failure and kidney failure[2-5] in the sub-Saharan African (SSA) region. It is a major contributor to overall mortality risk in adults in the region.[6] Hypertension also seems to be more common in urban than rural population[7] of the SSA region.

Specific risks associated with various blood pressure (BP) readings have largely been established for populations in many parts of the developed world but this is not the case for countries of the developing world including the SSA region. There is considerable evidence that long-term BP lowering to what is considered either normal or optimal levels results in several significant and important health benefits.[8] When established norms for ideal or optimal BP are applied to SSA populations, it becomes very evident that the vast majority of eligible patients do not enjoy the benefits of BP lowering therapies, either because of under-diagnosis or the many other barriers to BP lowering medications prescription, access and compliance in this setting.[1 2] As a case in point, a survey in Cameroon about eight years ago found that only 23% of all individuals with hypertension at the community level were aware of their status.[9] Moreover, only 46% of those aware (11% of all those with hypertension) were on treatment, among whom only 19% (2% of all those with hypertension) achieved expected target BP levels.[9]

There is also evidence that SSA is undergoing very rapid transitions characterized by increasing urbanization, including the adoption of unhealthy lifestyles.[10 11] These transitions are paralleled by changes in the profile of chronic disease risk factors including

1  
2  
3 blood pressure.[7] Recently there has been increasing awareness of the threat that the  
4  
5 looming chronic diseases pose to the health of the population in the Region at different  
6  
7 levels.[12] This increasing awareness has catalyzed initiatives aimed at improving access to  
8  
9 detection and care of chronic diseases including hypertension[13] in many countries of the  
10  
11 region. The pace of the above mutations suggests that, data on the burden of hypertension,  
12  
13 must be updated regularly, in order to provide the reliability needed in drawing-up health  
14  
15 service and policy solutions.  
16  
17

18  
19 The aim of this study was to assess the prevalence and determinants of hypertension, and  
20  
21 including the detection, treatment and control rates, as well as the variability by region and  
22  
23 gender in four major cities of Cameroon.  
24  
25

## 26 27 **Material and methods**

### 28 29 *Study population and settings*

30  
31 This was a cross-sectional population-based study conducted in the regional capitals of the  
32  
33 Centre (Yaounde), Littoral (Douala), North-West (Bamenda) and West (Bafoussam)  
34  
35 administrative regions (out of a total of ten) of Cameroon. According to the Cameroon  
36  
37 National Institute of Statistics,[14] the four participating regions had a total population of 9.98  
38  
39 million in 2010 (51% of the country's total population: 19.41 millions). In this same year,  
40  
41 57.5% of the national population was aged 15 years and above, and about 52% resided in  
42  
43 what was defined as an urban area.[14] During three consecutive weeks leading to the  
44  
45 specified day of the survey, daily announcements were made through radio and television,  
46  
47 inviting all interested adults (or individuals aged 15 years and above) to report to any of the  
48  
49 screening sites in participating cities. Such explanation included advice on the importance of  
50  
51 measuring and knowing one's blood pressure under the slogan "I know my blood pressure.  
52  
53 And you?". Announcements were also made in churches and market places. The study  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 protocol was approved by the Cameroon National Ethics Committee and signed informed  
4  
5 consent obtained from each participant.  
6

### 7 *Data collection*

8  
9  
10 The screening was conducted by trained medical personnel, simultaneously in the four cities  
11  
12 on the specified date of May 17<sup>th</sup> 2011. All participants were subjected to a face-to-face  
13  
14 interview during which data were collected (using a standardized questionnaire) on  
15  
16 demographics, smoking habits and alcohol consumption, physical activity, parental history of  
17  
18 hypertension, personal medical history (where the diagnosis was made by a physician) of  
19  
20 hypertension including drug treatment, diabetes mellitus, gout and dyslipidemia. The  
21  
22 physical examination included blood pressure (BP) and anthropometric measurements. BP  
23  
24 (systolic and diastolic) was measured using a standardized protocol with the [participant](#) in a  
25  
26 seated position, and after at least 10 minutes rest. [Participants](#) with evidence of recent (less  
27  
28 than 30 minutes) alcohol intake or smoking were invited to a 30 minutes rest before BP  
29  
30 measurement. BP measurements were performed on the right arm using automated  
31  
32 sphygmomanometers (OMRON M3 HEM-7200-E Omron Matsusaka Co Ltd, Japan). Special  
33  
34 attention was given to the use of appropriate cuff sizes (13×23 cm or 16×30 cm). Weight (to  
35  
36 the nearest 0.5 kg) was measured with the use of an automated scale. [Participants](#) were  
37  
38 permitted to keep on light clothing. Height (in meters to the nearest 0.5cm) was measured  
39  
40 using a wooden platform and a height rule. Body mass index (BMI in kg/m<sup>2</sup>) was calculated  
41  
42 as weight (kg)/[height (m) X height (m)]. Waist circumference was measured midway  
43  
44 between the iliac crest and the lower rib margin and the hip circumference was measured at  
45  
46 the intertrochanteric level. Waist-to-hip ratio (WHR) was calculated as waist (cm)/Hip (cm)  
47  
48 circumferences.  
49  
50  
51  
52  
53

### 54 *Definitions*

1  
2  
3 Respondents were classified as hypertensive if they had a systolic (and/or diastolic) BP of 140  
4 (90) mmHg or higher, or if they were on blood pressure lowering medications over the last 15  
5 consecutive days. Participants with hypertension were considered to be aware of their status if  
6 they answered 'yes' to the question 'have you ever been told by a doctor or health  
7 professional that you had hypertension?'. Treatment of high BP was defined by the use of BP  
8 lowering medications. Hypertension was considered to be controlled among treated  
9 individuals when systolic (and diastolic) SBP was < 140 (90) mmHg or <130 (80) mmHg in  
10 individuals with diabetes. Waist circumference >94 cm in men or 80 cm in women was  
11 considered to be high. Excessive alcohol consumption was based on intake of either more  
12 than three (two for women) standard glasses of wine per day or more than ten (five for  
13 women) local beers (1 local beer contains 28 g of alcohol) per week. Traditional alcohol  
14 beverages were not assessed. Participants who smoked at least one cigarette per day at the  
15 time of the study were classified as current smokers, and those who have smoked for at least 3  
16 years in the past, but had stopped by the time of the study were classified as former smokers.  
17  
18 Regular non-work related physical activity was considered in participants reporting at least 30  
19 min of intense physical activity, once a week or more.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

### 38 *Handling of participants with high blood pressure*

39  
40 Participants with hypertension (known or screened-detected) received on-site medical  
41 counseling and were referred back to their attending physician (known cases), or to specialists  
42 within the vicinity of the participant's residential area for workup and long-term management.  
43  
44 Few participants with excessively high BP with or without suspected acute target organ  
45 damage were immediately referred to emergency departments for appropriate care.  
46  
47  
48  
49  
50

### 51 *Statistical analysis*

52 Data analysis used the Statistical Package for Social Sciences (SPSS Inc, Chicago, IL) version  
53  
54 17.0 software. Results are summarized as count and percentages for qualitative variables and  
55  
56  
57  
58  
59  
60



1  
2  
3 mean and standard deviation (SD) for quantitative variables. Age-adjusted prevalence was  
4  
5 calculated using the Cameroon National population's age structure in 2010 as standard  
6  
7 population.[15] Direct standardization methods was applied.[16] Group comparisons used chi  
8  
9 square tests and equivalents for qualitative variables and Student t-test, analysis of the  
10  
11 variance (ANOVA) for quantitative variables. Logistic regressions analyses were used to  
12  
13 investigate potential determinants of prevalent hypertension and control. A p-value<0.05 was  
14  
15 used to characterize statistically significant results.

### Sensitivity analysis

The main analyses were based on a single blood pressure measurement. To assess the  
potential effects of 'regression to the mean' phenomenon on the prevalence of hypertension, a  
sensitivity analysis was conducted among participants with a raised initial blood pressure  
(SBP/DBP>=140/80 mmHg) and who had their blood pressure taken a second time on the  
same day. This analysis was based on the average of the first and second measurements.

## **Results**

### *The study population*

Two thousand one hundred and twenty eligible participants reported for screening in the four  
regions including 649 (30.6%) in the Centre, 1167 (54.1%) in the Littoral and 304 (14.3%) in  
the West and North West regions. Their overall profile including gender and region is  
summarized in Table 1. Participants included 1003 women (47.3%). Compared with men,  
women had similar age (43 vs. 44 years, p=0.19), similar waist circumference (93 vs. 93 cm,  
p=0.80), and similar history of diabetes mellitus, dyslipidemia and gout (all p≥0.07, Table 1).  
They were likely to have higher body mass index, higher prevalence of parental history of  
hypertension, lower systolic and diastolic blood pressure, and were less likely to be either a  
smoker or alcohol drinker and physically active (all p≤0.001. Table 1). With a few

1  
2  
3 exceptions, the above pattern was consistent within participating regions. However, the small  
4  
5 numbers of recruits in some subgroups translated into non-significant men/women differences  
6  
7 (Table 1). With the exception of smoking ( $p=0.07$ ), differences were also apparent in the  
8  
9 baseline profile across Regions (all  $p\leq 0.01$  for differences across regions).  
10

### 11 ***Blood pressure profile***

12  
13  
14 Mean systolic and diastolic BP (SD) at the total population level (men vs. women) was 139  
15  
16 (25) vs. 134 (28) mmHg ( $p<0.001$ ), and 83 (17) vs. 80 (17) mmHg ( $p=0.001$ ). Mean systolic  
17  
18 BP steadily increased with increasing age in men and women and across participating regions.  
19  
20 Diastolic BP also increased with increasing age, but only up to the fourth and fifth decade of  
21  
22 age, after which the pressure stabilized. This was observed in men and women and across  
23  
24 regions (Figure 1).  
25

26  
27 The distribution of participants by BP categories according to the 2003 ESH/ESC  
28  
29 classification [17] was examined by sex and regions, overall and by age groups is provided in  
30  
31 Table 2. An optimal BP was observed in 21.6% of men and 29.6% of women. The prevalence  
32  
33 of optimal or normal BP decreased with increasing age in men and women (all  $p\leq 0.001$  for  
34  
35 linear trend). Conversely, with the exception of grade 1 hypertension (both  $p\geq 0.09$  for  
36  
37 linearity) and high normal BP in women only ( $p=0.13$ ), the prevalence of all other BP  
38  
39 categories linearly increased with increasing age (all  $p<0.001$  for linear trend, Table 2).  
40  
41

42  
43 Similar trends were also observed across participating regions. However, the distribution of  
44  
45 participants across BP categories varied significantly by region ( $p<0.0001$ , Table 2)  
46

### 47 ***Prevalence of hypertension, and awareness and control rates***

48  
49 The prevalence of hypertension was 47.5% overall, and 50.1% and 44.6% in men and women  
50  
51 respectively ( $p<0.001$ ), Table 3. As expected, prevalence rate sharply increased with age  
52  
53 down from 31.7% (men) and 20.2% (women) in the age group <35 years, up to 77.6% (men)  
54  
55 and 75.2% (women) in the age group 55 years and above (Table 3). Awareness rate increased  
56  
57  
58  
59  
60

1  
2  
3 with increasing age in men and women (both  $p < 0.001$  for linear trend). Among participants  
4  
5 with hypertension, 24.6% in men and 40.5% in women were aware of their condition, and  
6  
7 those remaining were newly diagnosed. Of those aware of their hypertensive status, 57.9% in  
8  
9 men and 61.3% in women were on BP lowering medications, similarly across age groups in  
10  
11 men ( $p = 0.53$  for linear trend), and with a modest linearly increasing trend with age in women  
12  
13 ( $p = 0.03$ , Table 3). Among treated patients, 27.5% in men and 38.7% in women were at target  
14  
15 BP levels [i.e. systolic (and diastolic) BP  $< 140$  (90) mmHg], and similarly across age strata  
16  
17 (both  $p \geq 0.06$  for linear trend). Control rate was about 10% lower when the target BP level of  
18  
19  $< 130$  (80) was applied to participants with diabetes (Table 3).  
20  
21

22  
23 **Crude prevalence of hypertension, awareness and treatment varied significantly across**  
24  
25 **participating regions (all  $p < 0.001$ ). The highest crude prevalence (53.6%) was observed in the**  
26  
27 **Littoral region, while the highest crude awareness (60.9%) and treatment rates (49.0%) were**  
28  
29 **observed in provinces other than Centre ad Littoral (Table 3). Control rate was also higher in**  
30  
31 **those two region when the threshold level of 140/90 mmHg was applied to all treatments**  
32  
33 **participants ( $p < 0.001$ ). This difference however was non-significant when the threshold of**  
34  
35 **130/80 mmHg was applied to participants with diabetes. The age trends in prevalence,**  
36  
37 **awareness, treatment and control across regions were largely similar to those observed in men**  
38  
39 **and women (Table 3).**  
40  
41  
42

#### 43 ***Predictors of hypertension and control among urban dwellers***

44  
45 In unadjusted logistic regressions analysis, male gender, increasing age, Region, parental  
46  
47 history of hypertension, personal history of diabetes, gout, excessive alcohol consumption,  
48  
49 high BMI and high waist circumference were associated with prevalent hypertension (Table  
50  
51 4). In multivariable adjusted models, history of gout and excessive alcohol consumption were  
52  
53 no longer associated with prevalent hypertension. Table 5 shows the crude and adjusted odds  
54  
55 ratios (ORs) of hypertension control among treated patients. Male sex, high BMI and physical  
56  
57  
58  
59  
60

1  
2  
3 inactivity were associated with poor control of hypertension, while being from Regions other  
4  
5 than Centre or Littoral was associated with good control (Table 5).  
6

### 7 Sensitivity analysis

8  
9 Among participants with newly diagnosed hypertension based on the first blood pressure  
10 measurement (688 participants), 537 (78.0%) had a valid second measurement. Their mean  
11 blood pressure (SD) was 159.4 (19.0) for systolic and 94.4 (14.2) mmHg for diastolic based  
12 on the first measurement. Equivalents were 154.5 (19.0) and 93.0 (13.1) mmHg based on the  
13 average of the two measurements. Of the 537 participants 461 (85.8%) had hypertension  
14 (systolic/diastolic blood pressure  $\geq$  140/90 mmHg) using the average of the two blood  
15 pressure measurements.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

### 27 **Discussion**

28  
29 In this self-selected urban adult population study from Cameroon, we found a high  
30  
31 prevalence of hypertension, coupled with low detection, treatment and control rates. The high  
32  
33 prevalence was largely driven by age, as well as by gender and excess weight. However,  
34  
35 among those diagnosed and on treatment, control rate was similar across age groups, although  
36  
37 there were suggestions of regional differences, possibly reflecting underlying differences in the  
38  
39 access to healthcare and health resources utilization. Our ~~findings update previous reports on~~  
40  
41 ~~hypertension in Cameroon and~~ study provides comparative data across major cities in ~~the~~  
42  
43 ~~country~~ Cameroon and suggests findings compatible with previously reported high prevalence  
44  
45 rates of hypertension in the country.  
46  
47  
48

### 49 **Prevalence of hypertension**

50  
51 During the last ten years, at least two prevalence studies on hypertension have been reported  
52  
53 in urban Cameroon, applying similar definitions for hypertension, but different sampling  
54  
55 strategies.[7 9 18] The age-adjusted prevalence of hypertension in the current study is higher  
56  
57  
58  
59  
60

1  
2  
3 than that reported by Kamadjeu[9] in 2003, but similar to the findings of Fezeu[7] around that  
4  
5 same time. This balance of findings would tend to suggest that the prevalence of hypertension  
6  
7 in this setting is either stabilizing or growing at a much slower pace than previously  
8  
9 reported.[7]

10  
11 Elsewhere, available data on hypertension in Africa are from very heterogeneous studies, and  
12  
13 therefore offer less opportunities for reliable comparison.[3] Such heterogeneities include  
14  
15 differences in sampling methods and study settings (predominance of hospital based study),  
16  
17 the type of ~~subjects~~ participants enrolled, the measurements of blood pressure and definition  
18  
19 of hypertension, and the time period when the study was conducted.[19] Reliable, large-scale,  
20  
21 population-based data on high blood pressure in sub-Saharan Africa are very limited; however  
22  
23 available recent studies provide findings that demonstrate similarly high prevalence of  
24  
25 hypertension in urban settings.[20-22] Moreover, those findings already tend to be similar to  
26  
27 those reported in the developed world,[23 24] therefore, raising serious concerns given the  
28  
29 young age of clinical onset of hypertension in Africa.  
30  
31  
32

### 33 ***Awareness, treatment and control of hypertension***

34  
35  
36 In Cameroon, over the last ten years, there have been a number of initiatives aimed at scaling  
37  
38 up the fight against chronic diseases in general, and hypertension and diabetes mellitus in  
39  
40 particular,[25] including: 1) the adoption of a National Strategy for hypertension and  
41  
42 diabetes;[25] and 2) the development of training and task-shifting programmes to improve  
43  
44 detection and management at primary care level.[13 26] Findings from our study would tend  
45  
46 to suggest that the good will contained in the National Strategy has perhaps not yet been fully  
47  
48 translated into actions with sizable positive effects on the health of the population. For  
49  
50 instance, the Strategy aimed to improve level of risk factors by 25% and achieve optimal  
51  
52 control among those diagnosed with the condition.[25] However, we found awareness,  
53  
54 treatment and control rates which were within the range of those previous reported in  
55  
56  
57  
58  
59  
60

1  
2  
3 Cameroon prior to the adoption of the Strategy[7 9] and recently in other settings in  
4  
5 Africa.[20 22 25] The low awareness rate if confirmed, could be blamed on low detection  
6  
7 activity and accordingly non-optimal performance of the National strategy. It is also possible  
8  
9 that many participants already diagnosed with hypertension, and perhaps on treatment and  
10  
11 controlled on such treatment, did not feel the need to attend the screening campaign again.  
12  
13 This would have the undesirable effect of biasing our estimates by providing much lower than  
14  
15 the true figures. It is also possible that those with known and treated condition instead turned  
16  
17 out in higher number to use the campaign as an opportunity for their health checkup free of  
18  
19 charge. Our stratified analyses suggest that this mix could vary substantially by participating  
20  
21 centers. -In general however, low awareness of hypertension has been reported as a global  
22  
23 phenomenon,[27] although the magnitude may be less important in the developed world[23  
24  
25 28]. In the USA for instance, awareness of hypertension is as higher as 76%,[28] reflecting  
26  
27 the success achieved by a coordinated policy to detect individuals with higher-than-optimal  
28  
29 blood pressure levels.  
30  
31

32  
33 The low treatment and control rates in our study reflect the interplay between many factors  
34  
35 which were not directly captured by the current study. These include both patient-level,  
36  
37 healthcare provider level and health system level factors. Indeed, patients are expected to be  
38  
39 treated and controlled only if they can access appropriate health services, receive adequate  
40  
41 advice and prescriptions, and subsequently afford and adhere to those prescriptions.  
42  
43

44  
45 Accessibility to health care facility has likely improved in urban settings in Cameroon in  
46  
47 recent years. However the physician-to-population ratio, just like in many other countries in  
48  
49 the region, is still very low[29] and may explain the low awareness and treatment gaps.  
50

51  
52 Affordability of the cost of care also remains a major barrier in the study setting where out-of-  
53  
54 pocket spending is the main source of funding for healthcare costs. Adherence to prescribed  
55  
56 medications is another patient-level determinant of risk factor control not investigated in the  
57  
58

1  
2  
3 present study. Studies in Africa have shown that non-adherence to treatment and follow-up  
4 for hypertension was very common.[30-32] In one intervention study in Cameroon for  
5 instance, just about half of participants were still in the programme at 1-year of follow-up.[31]  
6  
7  
8

### 9 *Potential limitations and strengths of our study*

10  
11 The present study has some limitations. Participants were self-selected and may therefore not  
12 necessarily be representative of the general population in participating cities. Access to mass  
13 media (radio and television) is almost universal in major cities in the countries, and there is  
14 therefore no suggestion that advertisement of the campaign would have selectively reached  
15 certain portions of the population. It remains however; that participants in the study could still  
16 differ from the general population by being more or less health conscious, and having less  
17 severe disease for example, which could affect some parameters in the study. The study used  
18 a cross-sectional design, which precludes any causality inference. Diagnosis of hypertension  
19 was based on blood pressure measurements during a single encounter, which is at variant with  
20 guidelines recommendations for hypertension diagnosis using two measurements recorded on  
21 three separate occasions.[17] This may have overestimated the prevalence of hypertension  
22 and underestimated the level of blood pressure control. This however, would not affect  
23 comparisons with previous epidemiological studies that have used similar measurement  
24 methodology. Diagnosis of hypertension among those with no history of hypertension in our  
25 study was based on a single blood pressure measurement. Our sensitivity analysis suggests  
26 that this approach could inflated the crude prevalence by about 5.4% and 4.6% among those  
27 not known to have hypertension prior to the survey and at the total population level  
28 respectively. Nevertheless, even after accounting for this possible effect, our estimates would  
29 still be within sampling variation of the figures previously reported in this setting. It is also of  
30 note that no participant received a definitive diagnosis of hypertension as the result of taking  
31 part in this study. Those with elevated blood pressure levels were instead referred to health  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 | care facilities for further evaluation. The strengths of this study include the large sample of  
4  
5 the general population and, the rigorous collection of various lifestyle factors, medical data  
6  
7 and blood pressure measurements by trained staff according to standardized protocols, the  
8  
9 adequate standardization of prevalence and allowing comparisons with other African  
10  
11 countries. In addition, our sampling approach provides evidence that simple announcements  
12  
13 through mass media can attract from the community a large number of individual at risk of  
14  
15 undiagnosed hypertension.  
16

### 17 18 **Conclusions**

19  
20 | In conclusion, our study confirms-provides findings suggesting the high prevalence of  
21  
22 hypertension previously reported in urban settings in Africa. Detection, treatment and control  
23  
24 efforts are likely still well below optimal. This raises serious concerns about the prospects of  
25  
26 having to care very soon for both patients with higher-than-optimal blood pressure and many  
27  
28 more with target organ lesions subsequent to longstanding hypertension. There are already  
29  
30 some indications that the burden of stroke, end-stage renal disease and heart failure related to  
31  
32 hypertension is growing in the country and the region.[2 6 33]  
33  
34

### 35 36 **Perspectives**

37  
38 The low awareness, treatment and control rates of hypertension in this potentially health  
39  
40 conscious urban sub-Saharan population invite innovative approaches to improve prevention,  
41  
42 detection, treatment of hypertension beyond the traditional healthcare facilities based  
43  
44 approaches which are currently in force in many countries in the region.  
45  
46  
47  
48  
49  
50

51  
52 **Declaration of competing interest.** None for all authors.

53  
54 **Author contribution.** Dzudie and Kengne had full access to all of the data in the study and  
55  
56 takes responsibility for the integrity of the data and the accuracy of the data analysis.  
57  
58



1  
2  
3 Study concept and design: Dzudie, Kengne, Muna, Ngu, Kingue.  
4

5  
6 Acquisition of data: Ba, Menanga, Kouam Kouam, Abah, Monkam, Biholong, Mintom,  
7  
8 Kamdem, Djomou, Njebet, Ouambo, Luma,  
9

10  
11 Analysis and interpretation: Dzudie, Kengne, Muna  
12

13  
14 Drafting of the manuscript: Dzudie, Kengne, Muna  
15

16  
17 Critical revision of the manuscript for important intellectual content: all co-authors  
18  
19

## 20 21 22 **Acknowledgements** 23

24 The authors would like to express their gratitude to the following bodies and individuals for  
25 their contribution to the success of this study: 1) The Cameroon Ministry of public health for  
26 providing the blood pressure devices and health staff; 2) The executive committee and  
27 members of the Cameroon Cardiac Society for their support for data collection; 3) Servier  
28 Pharma Cameroon for a financial contribution to support data processing and drafting of the  
29 manuscript; 4) All specialist physicians, enthusiastic general practitioners, medical students  
30 and nurses involved in data collection; and 5) All those who helped at the different stages of  
31 the project and the fellow Cameroonians who volunteered across the four participating cities  
32 to take part in the study.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45  
46 **Data sharing statement:** No additional data available  
47

## 48 49 **Appendix 1** 50

51 Cameroon Cardiac Society (CCS) investigators group:  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 (1) Douala: Anastase Dzudie, Hamadou Ba, Henri Roger Ngote, Christian Biholong,  
4 Félicité Kamdem, Armel Djomou, Jules Njebet, Cyrille Ouambo, Roger Mboulley  
5 Kotto, Barbara Bouellet Abeng, Marielle Epacka Ewane Lobe and Yves Monkam.  
6  
7  
8  
9  
10 (2) Yaounde : Alain Menanga, Pierre Mintom, Euloge Yiagnigni, Mérimée Ouankou,  
11 Christophe Nouedoui, Pierre Ndobu, Marie Ntep, Monique Kenfack, Sylvie Ndongu,  
12 Martine Tchuem, Edvine Wawo, Walinjom F.T. Muna, Katleen Ngu Blackett and  
13 Samuel Kingue.  
14  
15  
16  
17  
18 (3) Bafoussam: Charles Kouam Kouam  
19  
20  
21 (4) Bamenda: Joseph Abah.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

### 33 References

- 34  
35  
36 1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of  
37 worldwide data. *Lancet* 2005;365:217-23.  
38  
39  
40 2. Kengne AP, Anderson CS. The neglected burden of stroke in Sub-Saharan Africa. *Int J*  
41 *Stroke* 2006;1:180-90.  
42  
43  
44 3. Addo J, Smeeth L, Leon DA. Hypertension in sub-saharan Africa: a systematic review.  
45 *Hypertension* 2007;50:1012-8.  
46  
47  
48 4. Kengne AP, Amoah AG, Mbanya JC. Cardiovascular complications of diabetes mellitus in  
49 sub-Saharan Africa. *Circulation* 2005;112:3592-601.  
50  
51  
52 5. Damasceno A, Cotter G, Dzudie A, et al. Heart failure in sub-saharan Africa: time for  
53 action. *J Am Coll Cardiol* 2007;50:1688-93.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 6. Kengne AP, Awah PK. Classical cardiovascular risk factors and all-cause mortality in rural  
4  
5 Cameroon. *Qjm* 2009;doi:10.1093/qjmed/hcn175.  
6
- 7 7. Fezeu L, Kengne AP, Balkau B, et al. Ten-year change in blood pressure levels and  
8  
9 prevalence of hypertension in urban and rural Cameroon. *J Epidemiol Community*  
10  
11 *Health* 2010;64:360-5.  
12
- 13 8. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular  
14  
15 events: results of prospectively-designed overviews of randomised trials. *Lancet*  
16  
17 2003;362:1527-35.  
18
- 19 9. Kamadjeu RM, Edwards R, Atanga JS, et al. Prevalence, awareness and management of  
20  
21 hypertension in Cameroon: findings of the 2003 Cameroon Burden of Diabetes  
22  
23 Baseline Survey. *J Hum Hypertens* 2006;20:91-2.  
24  
25
- 26 10. Leon DA. Cities, urbanization and health. *Int J Epidemiol* 2008;37:4-8.  
27
- 28 11. Popkin BM. Global nutrition dynamics: the world is shifting rapidly toward a diet linked  
29  
30 with noncommunicable diseases. *Am J Clin Nutr* 2006;84:289-98.  
31  
32
- 33 12. de-Graft Aikins A, Unwin N, Agyemang C, et al. Tackling Africa's chronic disease  
34  
35 burden: from the local to the global. *Globalization and health* 2010;6:5.  
36  
37
- 38 13. Lekoubou A, Awah P, Fezeu L, et al. Hypertension, diabetes mellitus and task shifting in  
39  
40 their management in sub-Saharan Africa. *Int J Environ Res Public Health* 2010;7:353-  
41  
42 63.  
43  
44
- 45 14. Cameroon's National Institute of Statistics. Statistical Yearbook 2010, 2011:39-52.  
46
- 47 15. Cameroon's National Institute of Statistics. Population du Cameroun en 2010, 2011.  
48
- 49 16. Woodward M, editor. *Epidemiology: study design and data analysis*. Second ed. New  
50  
51 York: Chapman & Hall/CRC, 2005.  
52
- 53 17. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of  
54  
55 Arterial Hypertension: The Task Force for the Management of Arterial Hypertension  
56  
57

- 1  
2  
3 of the European Society of Hypertension (ESH) and of the European Society of  
4  
5 Cardiology (ESC). *J Hypertens* 2007;25:1105-87.  
6  
7  
8 18. Kengne AP, Awah KP, Fezeu L, et al. The burden of high blood pressure and related risk  
9  
10 factors in urban sub-Saharan Africa: Evidences from Douala in Cameroon. *African*  
11  
12 *Health Sciences* 2007;7:38-44.  
13  
14 19. Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic  
15  
16 blood pressure since 1980: systematic analysis of health examination surveys and  
17  
18 epidemiological studies with 786 country-years and 5.4 million participants. *Lancet*  
19  
20 2011;377:568-77.  
21  
22  
23 20. Jenson A, Omar AL, Omar MA, et al. Assessment of hypertension control in a district of  
24  
25 Mombasa, Kenya. *Glob Public Health* 2011;6:293-306.  
26  
27  
28 21. Ulasi, II, Ijoma CK, Onodugo OD. A community-based study of hypertension and cardio-  
29  
30 metabolic syndrome in semi-urban and rural communities in Nigeria. *BMC Health*  
31  
32 *Serv Res* 2010;10:71.  
33  
34 22. Damasceno A, Azevedo A, Silva-Matos C, et al. Hypertension prevalence, awareness,  
35  
36 treatment, and control in mozambique: urban/rural gap during epidemiological  
37  
38 transition. *Hypertension* 2009;54:77-83.  
39  
40  
41 23. Wagner A, Sadoun A, Dallongeville J, et al. High blood pressure prevalence and control  
42  
43 in a middle-aged French population and their associated factors: the MONA LISA  
44  
45 study. *J Hypertens* 2011;29:43-50.  
46  
47  
48 24. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood  
49  
50 pressure levels in 6 European countries, Canada, and the United States. *Jama*  
51  
52 2003;289:2363-9.  
53  
54 25. Njamnshi AK, Bella Hiag A, Mbanya JC. From research to policy: the development of a  
55  
56 national diabetes programme in Cameroon. *Diabetes Voice* 2006;55:18-21.  
57  
58  
59  
60

- 1  
2  
3 26. Kengne AP, Sobngwi E, Fezeu L, et al. Setting-up nurse-led pilot clinics for the  
4  
5 management of non-communicable diseases at primary health care level in resource-  
6  
7 limited settings of Africa *PAMJ* 2009;3:10.  
8  
9  
10 27. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the  
11  
12 community: is the 'rule of halves' still valid? *J Hum Hypertens* 1997;11:213-20.  
13  
14 28. Cheung BM, Ong KL, Man YB, et al. Prevalence, awareness, treatment, and control of  
15  
16 hypertension: United States National Health and Nutrition Examination Survey 2001-  
17  
18 2002. *J Clin Hypertens (Greenwich)* 2006;8:93-8.  
19  
20  
21 29. World Health Organisation. Task shifting to tackle health worker shortage. Geneva, 2007.  
22  
23 30. Kengne AP, Awah PK, Fezeu LL, et al. Primary health care for hypertension by nurses in  
24  
25 rural and urban sub-Saharan Africa. *J Clin Hypertens (Greenwich)* 2009;11:564-72.  
26  
27  
28 31. Labhardt ND, Balo JR, Ndam M, et al. Improved retention rates with low-cost  
29  
30 interventions in hypertension and diabetes management in a rural African environment  
31  
32 of nurse-led care: a cluster-randomised trial. *Trop Med Int Health* 2011.  
33  
34 32. Dennison CR, Peer N, Steyn K, et al. Determinants of hypertension care and control  
35  
36 among peri-urban Black South Africans: the HiHi study. *Ethn Dis* 2007;17:484-91.  
37  
38 33. Halle MP, Kengne AP, Ashuntantang G. Referral of patients with kidney impairment for  
39  
40 specialist care in a developing country of sub-Saharan Africa. *Ren Fail* 2009;31:341-8.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Legend for figures and tables

**Figure 1:** Mean systolic and diastolic blood pressure by age groups for men (left panel) and women (right panel).

**Figure 2** – Blood pressure control among participants with hypertension according to the number of cardiovascular risk factors.

Risk factors considered were: overweight or obesity, high waist, current or past smoking, physical inactivity, diagnosed diabetes, dyslipidemia. None of the 116 participants with none of the risk factor had hypertension.

**Table 1 - General characteristics of the study population overall and by Region**

Characteristic	Regions										Overall		
	Centre			Littoral			North-West and West			p region	Men	Women	p
	Men	Women	P	Men	Women	P	Men	Women	p				
N	376	273		609	558		132	172		<0.001	1117	1003	
Mean age, yrs. (SD)	41 (12)	42 (14)	0.43	45 (13)	43 (14)	0.33	48 (14)	45 (14)	0.08	<0.001	44 (13)	43 (14)	0.19
Age groups, n			0.26			0.006			0.22	<0.001			0.01
<35 years	134	97		145	180		23	44			302	321	
35-44 years	99	57		154	108		32	40			285	205	
45-54 years	86	65		163	139		34	47			284	251	
≥55 years	57	54		146	131		43	41			246	226	
Mean BMI, kg/m <sup>2</sup> (SD)	26.2 (4.0)	27.2 (4.5)	0.002	26.9 (4.8)	29.0 (6.3)	<0.001	27.6 (5.0)	29.3 (5.4)	0.006	<0.001	26.7 (4.6)	28.6 (5.8)	<0.001
Waist girth, cm (SD)	96 (13)	94 (12)	0.04	91 (13)	91 (15)	0.31	95 (12)	97 (12)	0.15	<0.001	93 (13)	93 (14)	0.80
Mean SBP, mmHg (SD)	133 (22)	129 (24)	0.06	142 (26)	139 (30)	0.05	136 (25)	125 (25)	<0.001	<0.001	139 (25)	134 (28)	<0.001
Mean DBP, mmHg (SD)	77 (17)	77 (16)	0.98	85 (17)	82 (18)	0.001	85 (15)	79 (15)	0.001	<0.001	83 (17)	80 (17)	0.001
Parental hypertension, n	77	77	0.02	158	191	0.002	38	55	0.62	0.01	273	323	<0.001
History of diabetes, n	27	27	0.22	27	31	0.42	21	31	0.65	<0.001	75	89	0.07
History of dyslipidemia, n	1	0	>0.99	4	9	0.16	0	0	N/A	0.005	5	9	0.28
History of gout, n	0	1	0.42	13	9	0.53	1	0	0.43	<0.001	14	10	0.68
Physical activity, n	160	86	0.004	334	180	<0.001	82	104	0.77	<0.001	576	370	<0.001
Smoking, n			<0.001			<0.001			<0.001	0.07			<0.001
Never	320	267		500	540		113	170			933	977	
Former	21	26		43	7		4	0			68	12	
Current	35	36		66	11		15	2			116	14	
Excessive alcohol, n	85	17	<0.001	147	51	<0.001	51	32	<0.001	<0.001	283	100	<0.001

BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; SD, standard deviation

**Table 2 - Hypertension prevalence, awareness and control among self-selected urban dwellers in Cameroon**

Gender Region	Variable	Overall	Overall*	Age groups (years)				P-trend	
				<35	35-44	45-54	≥55		
Centre	Prevalence (%)	35.4	27.3 (23.3-31.3)	15.1	28.2	48.3	70.3	<0.001	
	SBP/DBP≥140/90 mmHg or treatment (n)	230	230	35	44	73	78		
	Awareness (%)	30.4	12.5 (9.3-15.7)	0	22.7	31.5	47.4	<0.001	
	Among hypertensives (n)	70	70	0	10	23	37		
	Treatment (%)	61.4	21.9 (13.6-30.2)	NA	50.0	52.2	70.3	0.13	
	Among aware hypertensives (n)	43	43	NA	5	12	26		
	Control A (%)	25.6	6.7 (2.5-10.9)	NA	0	33.3	26.9	0.41	
	Among treated hypertensive (n)	11	11	NA	0	4	7		
	Control B (%)	25.6	6.7 (2.5-10.9)	NA	0	33.3	26.9	0.41	
	Among treated hypertensive (n)	11	11	NA	0	4	7		
	Littoral	Prevalence (%)	53.6	43.6 (39.2-48.0)	33.8	45.0	61.7	76.2	<0.001
		SBP/DBP≥140/90 mmHg or treatment (n)	626	626	110	118	187	211	
		Awareness (%)	25.1	15.1 (11.3-18.9)	9.1	11.9	25.1	40.8	<0.001
		Among hypertensives (n)	157	157	10	14	47	86	
Treatment (%)		49.0	38.7 (16.7-60.7)	30.0	57.1	46.8	51.2	0.42	
Among aware hypertensives (n)		77	77	3	8	22	44		
Control A (%)		18.2	26.8 (-13.7 to 67.3)	33.3	12.5	22.7	15.9	0.60	
Among treated hypertensive (n)		14	14	1	1	5	7		
Control B (%)		18.2	26.8 (-13.7 to 67.3)	33.3	12.5	22.7	15.9	0.60	
Among treated hypertensive (n)		14	14	1	1	5	7		
Others		Prevalence (%)	49.7	34.4 (26.6-42.2)	22.4	30.6	51.8	85.7	<0.001
		SBP/DBP≥140/90 mmHg or treatment (n)	151	151	15	22	42	72	
		Awareness (%)	60.9	30.3 (17.7-42.9)	13.3	40.9	53.5	77.8	<0.001
		Among hypertensives (n)	92	92	2	9	25	56	
	Treatment (%)	77.7	91.6 (5.6-178)	100	77.8	84.0	73.2	0.30	
	Among aware hypertensives	71	71	2	7	21	41		
	Control A (%)	31.0	12.9 (4.7-21.1)	0	42.9	14.3	39.0	0.22	
	Among treated hypertensive (n)	22	22	0	3	3	16		
	Control B (%)	56.3	51.5 (-9.7 to 113)	50.0	57.1	33.3	68.3	0.12	
	Among treated hypertensive (n)	40	40	1	4	7	28		
	Men	Prevalence (%)	50.1	41.3 (36.9-45.7)	31.7	38.9	57.2	77.6	<0.001
		SBP/DBP≥140/90 mmHg or treatment (n)	560	560	96	111	162	191	
		Awareness (%)	24.6	13.5 (10.0-17.0)	6.3	12.6	21.6	43.5	<0.001
		Among hypertensives (n)	138	138	6	14	35	83	
Treatment (%)		57.9	54.6 (19.3-89.9)	50	64.2	65.7	54.2	0.53	
Among aware hypertensives		80	80	3	9	23	45		
Control A (%)		18.8	28.2 (-12.0 to 68.6)	33.3	22.2	21.7	15.5	0.36	
Among treated hypertensive (n)		15	15	1	2	5	7		
Control B (%)		27.5	50.3 (-6.3 to 107)	66.6	22.2	26.1	26.7	0.49	
Among treated hypertensive (n)		22	22	2	2	6	12		
Women		Prevalence (%)	44.6	32.5 (28.8-36.2)	20.2	35.6	55.8	75.2	<0.001
		SBP/DBP≥140/90 mmHg or treatment (n)	447	447	64	73	140	170	
		Awareness (%)	40.5	20.9 (15.6-26.2)	9.3	26.0	42.8	54.5	<0.001
		Among hypertensives (n)	181	181	6	19	60	96	
	Treatment (%)	61.3	43.3 (13.9-72.7)	33.3	57.9	53.3	68.9	0.03	
	Among aware hypertensives	111	111	2	11	32	66		
	Control A (%)	28.8	8.0 (4.6-13.8)	0	18.1	21.8	34.8	0.08	
	Among treated hypertensive (n)	32	32	0	2	7	23		
	Control B (%)	38.7	12.8 (7.2-18.4)	0	2.7	31.3	45.5	0.06	
	Among treated hypertensive (n)	43	43	0	3	10	30		

Data are percentages with numerators below. Control A, blood pressure below 140/90 mmHg or 130/80 mmHg among diabetic patients; Control B, blood pressure below 140/90 mmHg among all subjects/participants. DBP, diastolic blood pressure; NA, not applicable SBP, systolic blood pressure.

\* Age standardized according to the 2010 Cameroon national population distribution.



**Table 3 - Crude and adjusted odds ratios for predictors of hypertension among self-selected urban dwellers in Cameroon.**

Variable	Category	Unadjusted odd ratios (95% CI)	p	Adjusted odd ratios (95% CI)*	p
Sex	Men	1.25 (1.05-1.48)	0.01	1.63 (1.34-2.00)	<0.001
Age	<35 years	1 (reference)	<0.001	1 (Reference)	<0.001
	35-44 yrs	1.74 (1.35-2.25)		1.32 (1.01-1.73)	
	45-54 yrs	3.75 (2.93-4.81)		2.81 (2.16-3.64)	
	≥55 yrs	9.41 (7.12-12.43)		8.27 (6.19-11.04)	
Region	Centre	1 (Reference)	<0.001	1 (Reference)	<0.001
	Littoral	2.11 (1.73-2.57)		1.89 (1.52-2.36)	
	Others	1.80 (1.36-2.37)		1.38 (1.01-1.89)	
Parental hypertension	Yes	1.47 (1.21-1.77)	<0.001	1.55(1.25-1.92)	<0.001
Diabetes mellitus	Yes	3.77 (2.61-5.44)	<0.001	2.63 (1.75-3.94)	<0.001
Dyslipidemia	Yes	2.00 (0.67-5.98)	0.22	1.55 (0.47-5.11)	0.47
Gout	Yes	3.36 (1.33-8.49)	0.01	1.70 (0.62-4.67)	0.30
Smoking	Never	1 (Reference)	0.11	1 (Reference)	0.62
	Former	1.59 (1.01-2.51)		0.96 (0.59-1.65)	
	Current	0.90 (0.63-1.29)		0.82 (0.54-1.22)	
Physical activity	No	0.90 (0.76-1.07)	0.23	1.13 (0.93-1.38)	0.21
Excessive alcohol	Yes	1.33 (1.06-1.66)	0.01	1.05 (0.81-1.36)	0.70
Body mass index	Normal	1 (Reference)	<0.001	1 (Reference)	<0.001
	Overweight	2.03 (1.65-2.50)		1.94 (1.54-2.45)	
	Obese	3.54 (2.83-4.43)		3.32 (2.57-4.29)	
High waist girth		2.12 (1.78-2.52)	<0.001	1.94 (1.51-2.48)	<0.001

\* age, sex, parental history of hypertension, body mass index and region adjusted; CI, confidence interval


**Table 4 - Crude and adjusted odds ratios for predictors of hypertension control among self-selected and treated hypertensives in four main cities of Cameroon.**

Variable	Category (%)	Unadjusted odd ratios (95% CI)	P	Adjusted odd ratios (95% CI)*	p
Sex	Men	0.59 (0.35-1.00)	0.05	0.47 (0.26-0.86)	0.01
Age	<35 years	1.00 (Reference)	0.87	1.00 (Reference)	0.63
	35-44 yrs	0.54 (0.12-2.32)		0.38 (0.07-1.99)	
	45-54 yrs	0.68 (0.19-2.45)		0.57 (0.13-2.41)	
	≥55 yrs	0.67 (0.19-2.34)		0.46 (0.11-1.88)	
Region	Centre	1.00 (Reference)	<0.001	1.00 (Reference)	<0.001
	Littoral	0.72 (0.35-1.50)		0.70 (0.33-1.52)	
	Others	3.36 (1.64-6.87)		3.50 (1.65-7.42)	
Parental hypertension	Yes	1.44 (0.87-2.40)	0.16	1.56 (0.89-2.75)	
Diabetes mellitus	Yes	2.73 (1.60-4.67)	<0.001	1.83 (0.98-3.39)	0.06
Dyslipidemia	Yes	0.74 (0.08-6.75)	0.79	1.30 (0.13-13.26)	0.83
Gout	Yes	NA (None)			
Smoking	Never	1.00 (Reference)	0.53	1.00 (Reference)	0.72
	Former	0.79 (0.21-2.89)		1.26 (0.30-5.34)	
	Current	0.32 (0.04-2.57)		0.44 (0.05-3.97)	
Physical activity	No	0.30 (0.17-0.56)	<0.001	0.36 (0.20-0.66)	0.001
	Excessive	0.59 (0.26-1.32)		0.64 (0.26-1.60)	
Body mass index	Normal	1.00 (Reference)	0.002	1.00 (Reference)	0.003
	Overweight	0.41 (0.22-0.77)		0.44 (0.22-0.90)	
	Obese	0.34 (0.18-0.66)		0.28 (0.14-0.59)	
High waist girth		0.86 (0.51-1.44)	0.56	0.77 (0.33-1.77)	0.54

\* age, sex, parental history of hypertension, body mass index and region adjusted; CI, confidence interval.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Figure 1:



1  
2  
3 **Manuscript ID bmjopen-2012-001217 entitled "Prevalence, awareness, treatment and**  
4 **control of hypertension in a self-selected sub-Saharan African urban population: A**  
5 **cross-sectional study**  
6  
7

8  
9  
10 Dear Editor,

11  
12  
13  
14 We are grateful to the reviewers for their time and very constructive comments on our  
15 manuscript.  
16

17  
18 We have used those comments to improve our work and wish to submit an updated version  
19 for further consideration for publication in the Journal.  
20

21  
22 In particular, to overcome the issue of single BP measurement, we now report sensitivity  
23 analyses based on data for nearly 80% of those diagnosed with hypertension based on a  
24 single measurement, and who also had a second BP measurement on the same day. The  
25 results based on the average of two BP measurements do not support a massive inflation of  
26 our results. Similarly, we also provide more stratified results by city now.  
27  
28

29  
30 Changes in the new version of the manuscript appear with the tack changes indication or red  
31 colour in tables.  
32

33  
34 We also provide a point-by-point response to each comment from the reviewer. Each time  
35 our response includes material from the manuscript, it is indicated in *italic* and **in black**  
36 colour if such a material was already present in the original version of the manuscript or in  
37 **red colour** for new material.  
38

39  
40 We look forward to the outcome of your assessment.  
41

42 Yours sincerely,  
43 Andre Pascal Kengne  
44 On behalf of the co-authors  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Reviewer(s)' Comments to Author:**

Reviewer: Dr Juliet Addo

Lecturer, London School of Hygiene and Tropical Medicine, UK

The participants included in the study are not representative of the general Cameroon population as they were self-selected. The authors have however acknowledged this as a limitation of the study.

This paper addresses an important health problem in sub Saharan Africa (SSA) where previous studies have highlighted the high prevalence of hypertension particularly in urban areas. It is well written and adds to the available evidence from the sub region. There are however a few issues that require addressing or clarification.

The authors state the aims clearly including assessing the variability of the prevalence and determinants by region and gender which is clearly an interesting aspect of this paper particularly if there are significant differences between these regions in terms of perhaps level of urbanisation or occupation. This information is not clearly given and the prevalence, awareness, control etc is not reported by the regions except for the graph showing the mean blood pressure readings. I am also not certain why there were such differences in the number reporting from each of the cities sampled.

**Our response:** Thank you for raising this point. We have addressed the issue by updating the former Table 3 (now Table 2) to introduce region-specific data, in addition to those on gender. The result section has also been updated to reflect this change.

Differences in the number of participants across regions likely reflect differences in the sizes of the background population of the participating cities. For instance Yaounde (Centre region) and Douala (Littoral region) have got population sizes in the region of 1.3 to 1.5 million, while Bafoussam (West region) and Bamenda (North-West region) have less than 0.5 million population each.

The method of recruitment which was by self-selection could potentially have biased the participation and over-estimated the prevalence of hypertension as was discussed by the authors. Could this have affected the response to the survey from particular cities more than others?

**Our response:** Analyses stratified by region (Table 2 and 3) suggest that participants from regions other than Centre and Littoral likely included relatively more participants who were aware of their status for hypertension, and likely receiving treatment. However, the relatively small number of participants from those regions would not significantly affect the overall results.

The authors do state the measurement of blood pressure on one visit only as a limitation. This is clearly important. In most similar studies several readings of blood pressure have been taken on the same day where it was not possible to arrange for a repeat visit and the average of two or three readings determined. There is however no reporting of this being done in this study where it appears only one measurement was taken.

**Our response:** Based on the predefined protocol of the survey and to limit the workload for the staff (given the limited staff number) and waiting time for participants, only those

1  
2  
3 participants with an abnormal first reading were requested to have a second BP measurement.  
4 Even on such a protocol, some participants with raised BP left without having their second  
5 BP measured, and few other second measurements failed to be reported in some participants.  
6 Overall, of the 688 participants not known to suffer from hypertension and who had a raised  
7 BP (SBP/DBP $\geq$ 140/90) based on the first measurement, a second valid measurement was  
8 available for 537 (78%). We have now repeated the analysis and found that among the 537,  
9 85.8% (462 participants) had raised BP based on the average of the two measurements. This  
10 at the population level will translate into about 5% point overestimation of the prevalence of  
11 new hypertension based on a single measurement. We have added this new information as a  
12 sensitivity analysis indicated both in the methods, results and discussion chapters. The  
13 relevant sections read:  
14

15  
16 In the method section:

17  
18 **“Sensitivity analysis**

19  
20 *The main analyses were based on a single blood pressure measurement. To assess the*  
21 *potential effects of ‘regression to the mean’ phenomenon on the prevalence of hypertension, a*  
22 *sensitivity analysis was conducted among participants with a raised initial blood pressure*  
23 *(SBP/DBP $\geq$ 140/80 mmHg) and who had their blood pressure taken a second time on the*  
24 *same day. This analysis was based on the average of the first and second measurements.”*  
25  
26

27  
28 In the result section

29  
30 **“Sensitivity analysis**

31  
32 *Among participants with newly diagnosed hypertension based on the first blood pressure*  
33 *measurement (688 participants), 537 (78.0%) had a valid second measurement. Their mean*  
34 *blood pressure (SD) was 159.4 (19.0) for systolic and 94.4 (14.2) mmHg for diastolic based*  
35 *on the first measurement. Equivalent values were 154.5 (19.0) and 93.0 (13.1) mmHg based on the*  
36 *average of the two measurements. Of the 537 participants 461 (85.8%) had hypertension*  
37 *(systolic/diastolic blood pressure $\geq$ 140/90 mmHg) using the average of the two blood*  
38 *pressure measurements.”*  
39  
40

41  
42 In the discussion, under the limitation section

43  
44 *“Diagnosis of hypertension among those with no history of hypertension in our study was*  
45 *based on a single blood pressure measurement. Our sensitivity analysis suggests that this*  
46 *approach could have inflated the crude prevalence by about 5.4% and 4.6% among those not*  
47 *known to have hypertension prior to the survey and at the total population level respectively.*  
48 *Nevertheless, even after accounting for this possible effect, our estimates would still be within*  
49 *sampling variation of the figures previously reported in this setting. It is also of note that no*  
50 *participant received a definitive diagnosis of hypertension as the result of taking part in this*  
51 *study. Those with elevated blood pressure levels were instead referred to health care*  
52 *facilities for further evaluation.”*  
53  
54

55  
56 Was there a measure of socioeconomic status such as level of education or wealth and could  
57 this be a predictor of hypertension prevalence and control?  
58  
59  
60

1  
2  
3  
4 **Our response:** Unfortunately, we did not collect data on these important predictors.  
5

6 The authors did not state that they aimed to determine the level of hypertension control  
7 according to the number of risk factors and so I am uncertain what Figure 2 adds to the study.  
8 Was the plan to study total cardiovascular risk as well? Table 2 also reporting on blood  
9 pressure categories in participants could also be presented by a few sentences in the results  
10 section.  
11

12 The manuscript could therefore be shortened considerably.  
13

14 **Our response:** We have now removed the table 2 and kept only the narrative summary in the  
15 results section. We have also removed the Figure 2 and all reference to that figure as well.  
16

17 Minor comment is to stick to the term participants instead of subjects.  
18

19 **Our response:** We now use 'participants' throughout  
20

21 Overall, this paper adds to the literature that reflects the lack of awareness, treatment and  
22 control of hypertension in SSA and highlights the need for addressing these effectively.  
23

24 **Our response:** Thank you for the appreciation  
25  
26

27  
28 Reviewer: Dr Niklaus Daniel Labhardt, MD MIH SolidarMed Seboche Hospital Botha-Bothe  
29 Lesotho  
30

31 I have no conflicts of interest to be declared  
32  
33

34 Overall Study Design:

35 The authors state, the objective is to "quantify the burden ... of hypertension, treatment and  
36 control rates among adults in major cities in Cameroon". These objectives can not be  
37 answered by the study design applied in this paper for two reasons:  
38

39 1. To assess the burden, treatment and control rates among adults in urban Cameroon, one  
40 should use another sampling method than the one used in the study. This study used persons  
41 who attended by their own motivation a screening campaign. The study sample can therefore  
42 not be considered as being representative and therefore not provides information about the  
43 overall burden and control-rates in urban Cameroon.  
44

45 2. A single BP-measurement per individual is not reliable. It may lead to a substantial  
46 overestimation of the prevalence. (see: Bovet, P., Gervasoni, J.P., Ross, A.G., Mkamba, M.,  
47 Mtasiwa, D.M., Lengeler, C., Burnier, M. & Paccaud, F., 2003, Assessing the prevalence of  
48 hypertension in populations: are we doing it right? Journal of hypertension, 21(3), pp. 509-  
49 17.)  
50

51  
52 The two limitations are acknowledged under limitations. However, the first one is not a  
53 limitation. In my view it is a recruitment bias.  
54

55 **Our answer:** Thank you for raising these points, which as recognised by the reviewer have  
56 been highlighted in the limitation section of the manuscript. We feel that both are potential  
57 sources of biases ('selection bias' for the 1<sup>st</sup> and 'regression to the mean' for the second). We  
58  
59  
60



1  
2  
3 feel that the 'limitation section' of the article is the place where all issues from the study  
4 conception through to data analysis and reporting, that can potentially affect the internal and  
5 or external validity of the study are acknowledged.  
6

7  
8 With regard to point 1, we have made no claim that our sample was representative of the  
9 background Cameroonian population in participating cities, and would refrain from doing so.  
10 We have rather discussed extensively on those factors that could potentially make our sample  
11 to be different from the background population. The most we could do was to attempt to  
12 control some of the possible biases that could result from our sampling approach; through  
13 reporting of the age and standardised estimates for instance. We now even provide those  
14 standardised estimates by participating city. We also have to acknowledge the challenges of  
15 conducting a representative population-based survey in a country where no household  
16 numbering has been implemented, and with virtually no funding as done for the current  
17 study. In such a context, previous studies have been conducted by selecting for instance a  
18 suburb in a given city (supposedly representative of the population of the city), then  
19 enumerating the household to allow a random sample. That our results are in major ways  
20 similar to those from those from those studies perhaps suggests that the two approaches have  
21 possibly captured the same characteristics in the population. Therefore, our results have  
22 utility in the context of those available.  
23

24  
25 With regard to point 2, please see our answer to reviewer #1 on the further steps we have  
26 undertaken to quantify the possible magnitude of the overestimation induced by our reliance  
27 on a single BP measurement. Our sensitivity analyses suggest that the approach could have  
28 inflated the crude prevalence by about 5% point. Even accounting for such an effect the  
29 prevalence would still be high, reflecting the background high prevalence reported in  
30 previous studies. We do however recognised that this may not be the more appropriate  
31 approach for assessing BP levels in surveys and have again emphasized it in the limitation  
32 section.  
33

34  
35 Overall English is good. However, some of the wording may be checked again.  
36

37 **Our answer:** We have checked the manuscript again and fixed those wording issues  
38 identified.  
39

#### 40 DISCUSSION:

41 The subsection on prevalence of hypertension should be reviewed. I think the present study  
42 cannot add any evidence to prevalence in the Cameroon population (see above).  
43 The subsection on awareness should equally be reviewed based on the same problem of self-  
44 selection.  
45  
46

47 **Our answer:** Thank you for raising this point. We have now removed the claim that our  
48 study updates the prevalence of hypertension in country. We however feel that it is still  
49 important to cautiously discuss our findings in the context of available data, as this provide of  
50 opportunity of speculating on the possible biases introduced by the methodological  
51 limitations discussed above.  
52

#### 53 54 55 CONCLUSION:

56  
57  
58  
59  
60



1  
2  
3 The conclusion "In conclusion, our study confirms the high prevalence of hypertension  
4 previously reported in urban settings in Africa. Detection, treatment and control efforts are  
5 still well below optimal." cannot be made based on this study (see above).  
6

7 **Our answer:** We have changed the wording. It now reads:  
8

9  
10 *"In conclusion, our study provides findings suggesting the high prevalence of hypertension*  
11 *previously reported in urban settings in Africa. Detection, treatment and control efforts are*  
12 *likely still well below optimal."*  
13

14 In general the paper is very well written, statistical methods are appropriate and the results  
15 are well presented. However, I think due to the selection bias, the study does not answer its  
16 major objective. The subsequent detailed analyses about predictors of hypertension in this  
17 specific population are indeed correct. However, it is nothing new and as a considerable  
18 number of the individuals diagnosed being hypertensive in this study may in reality be  
19 normotensive, the usefulness of these analyses are questionable to me.  
20

21 I fully acknowledge the importance of hypertension in sub-Saharan Africa and basically any  
22 publication about this topic is welcome. However, I doubt if the findings of this study really  
23 contribute to our knowledge due to the selection bias and the one single-reading procedure. I  
24 would recommend to shorten the manuscript considerably and to resubmit it as a brief report  
25 or short communication, summarizing the findings from screening campaigns in 3 different  
26 urban settings in Cameroon. (MANAGING EDITOR'S NOTE - please note BMJ Open does  
27 not publish short reports; if you wish to do this you will need to submit elsewhere)  
28

29  
30 **Our answer:** We thank the reviewer for his appreciation. We are well aware of the potential  
31 effects of the issues raised on our findings and have discussed them at length in the  
32 manuscript. We remain however of those who believe that 'the perfect' shouldn't be the  
33 enemy of 'the possible' and would prefer to strive with the little means available to us, to  
34 generate any evidence that can potentially inform health service and policy solutions. We also  
35 believe that keeping a full paper aid the provision of detailed information with potential  
36 utility locally and even beyond.  
37

38 Reviewer: Albertino Damasceno  
39 Professor of Cardiology, Eduardo Mondlane University Maputo, Mozambique  
40

41 I have no conflict of interests.  
42

43  
44 This interesting study that evaluated hypertension and other cardiovascular risk factors in a  
45 large population and in 4 different cities has in our opinion two major problems.

46 The sample used to evaluate the prevalence of hypertension was based on a group of self-  
47 selected adults that voluntary came to be evaluated. Although some recent papers have been  
48 published using the same methodology, this should be not accepted as a standard  
49 epidemiological methodology. With this sample it is not possible to generalize the results  
50 neither to the urban population of Cameroon nor to the national population.  
51

52 This can be clearly seen in the large differences of people that was observed in the 4 different  
53 cities – a very small group of people observed in 2 regions in the West and North West  
54 regions (304 - 14.3%) compared with a large group that came in the littoral (1167 - 54.1%).  
55

56 This turns any comparison among regions very unlikely.  
57  
58  
59  
60

1  
2  
3 **Our response:** Thank you for the appreciation and for raising this point which we have  
4 addressed already above (see our answer to reviewer #1). There are true differences in the  
5 population size of the participating cities, with Douala and Yaounde being much larger than  
6 Bafoussam and Bamenda. Everything else being equal, one would expect fewer participants  
7 from the latter, which is been reflected in the turn out numbers by city in our study.  
8  
9

10  
11 Another way to see that the sample is not a representative one is the division of the  
12 participants by age groups. While in the Center city the younger group is the largest and the  
13 older the smaller as expected in the other 3 regions the sample shows the contrary with the  
14 older being more common than the younger denoting a non-representative sample of the  
15 population.  
16

17  
18 **Our response:** We have attempted to address this point now by providing age standardised  
19 prevalence by participating city. Please see the new table 2 in the main manuscript.  
20

21 Big differences between the mean systolic and diastolic blood pressures of the center city and  
22 the other ones are shown as well as very big differences in the prevalence of self-reported  
23 diabetes in men between the Center city (about 4%) and the West and North west cities  
24 (about 16%). In our opinion, if not explained, this reflects the bias in the selection of the  
25 participants.  
26

27  
28 **Our response:** We now report the age-standardised prevalence by participating centres,  
29 which suggest differences by city in prevalence, awareness and treatment. In the absence of  
30 specific data on the background access to hypertension diagnosis and care by city, it is very  
31 difficult to speculate on the likely direction of the effect of possible bias if any. We have  
32 however provided the following points in the discussion.  
33  
34

35 *“It is also possible that many participants already diagnosed with hypertension, and perhaps*  
36 *on treatment and controlled on such treatment, did not feel the need to attend the screening*  
37 *campaign again. This would have the undesirable effect of biasing our estimates by providing*  
38 *much lower than the true figures. It is also possible that those with known and treated*  
39 *condition instead turned out in higher number to use the campaign as an opportunity for*  
40 *their health checkup free of charge. **Our stratified analyses suggest that this mix could vary***  
41 *substantially by participating centers.”*  
42  
43  
44  
45

46 The second problem that is not clear in the methodology is how was the blood pressure  
47 measured? The value of the blood pressure used to classify these adults as  
48 hypertensive/normotensive patients is the result of a single measurement or the mean of  
49 several measurements? The measurement during a single encounter was already used in  
50 several epidemiological studies and is the methodology proposed by WHO in the STEP wise  
51 approach but this value should be the mean of 3 consecutive measurements. The authors do  
52 not specify how many measurements have done in each participant. If only one measurement  
53 was done, like is understandable in the methodology of the paper, the discriminative power of  
54 this single measurement is very poor and this should be clearly stress in the methodology and  
55 the discussion.  
56  
57  
58  
59  
60

1  
2  
3 **Our response:** Please refer to our answer to reviewer 1 on this point above.  
4  
5

6 Just three other small remarks:  
7

8 Line 18 on page 8 >94 in men and >80 in women  
9

10 **Our response:** This was based on the IDF definition of metabolic syndrome.  
11  
12

13 Alcohol consumption was done using just beer or wine consumption. Was the consumption  
14 of traditional alcoholic beverages or whisky and other distillates also evaluated?  
15  
16

17 **Our response:** We thank the reviewer for this remark. Alcohol consumption was based on  
18 self-reported beer, wine and whisky consumption. Traditional alcoholic beverage was not  
19 evaluated in this study.  
20  
21

22 The classification of a current smoker as someone who stop smoking for less than 3 years is a  
23 very particular one and probably result in an over estimation of smokers.  
24  
25

26 **Our response:** We do agree that the wording is somehow inaccurate and misleading. Please  
27 read:  
28  
29

30 *“Participants who smoked at least one cigarette per day at the time of the study were*  
31 *classified as current smokers, and those who have smoked for at least 3 years in the past, but*  
32 *had stopped by the time of the study were classified as former smokers.”*  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any pre-specified hypotheses	5-6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6-8
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	7-8
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	8-9
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	8-9

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	9
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	9-10
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	11
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14-15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-14
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).



**Prevalence, awareness, treatment and control of hypertension in a self-selected sub-Saharan African urban population: A cross-sectional study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001217.R2
Article Type:	Research
Date Submitted by the Author:	20-Jul-2012
Complete List of Authors:	Dzudie, Anastase Kengne, Andre; South African Medical Research Council, National Collaborative Programme on Cardiovascular and metabolic Disease; The George Institute for Global Health, Muna, Walinjom Ba, Hamadou Menanga, Alain Kouam Kouam, Charles Abah, Joseph Monkam, Yves; General Hospital of Douala, Department of Internal Medicine Biholong, Christian; General Hospital of Douala, Department of Internal Medicine Mintom, Pierre Kamdem, Felicite; General Hospital of Douala, Department of Internal Medicine Djomou, Armel; General Hospital of Douala, Department of Internal Medicine Ndjebet, Jules; General Hospital of Douala, Department of Internal Medicine Ouambo, Cyrille Luma, Henry; General Hospital of Douala, Department of Internal Medicine Ngu, Kathleen Kingue, Samuel
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Global health, Epidemiology
Keywords:	Hypertension < CARDIOLOGY, EPIDEMIOLOGY, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts

1  
2  
3 **Prevalence, awareness, treatment and control of hypertension in a self-selected sub-**  
4  
5 **Saharan African urban population: A cross-sectional study**  
6  
7

8 **Short title:** Awareness, treatment and control of hypertension  
9

10 Anastase Dzudie, MD, FESC(1); André Pascal Kengne, MD, PhD(2); Walinjom F.T. Muna, MD,  
11 PhD, FACC(3); Hamadou Ba, MD(1); Alain Menanga, MD (4); Charles Kouam Kouam MD(5);  
12 Joseph Abah, MD(6); Yves Monkam, MD(1); Christian Biholong, MD(1); Pierre Mintom MD(4);  
13 Félicité Kamdem, MD(1); Armel Djomou, MD(1); Jules Ndjebet, MD(1); Cyrille Ouambo, MD,  
14 PhD(1); Henri Luma, MD(1), Katleen Blackett Ngu, MD, FESC(6); Samuel Kingue, MD(6); On  
15 behalf of the CCS investigator group\*.  
16  
17  
18  
19  
20  
21

22 (1) Department of Internal Medicine, Douala General Hospital and Buea Faculty of medicine,  
23 Cameroon  
24  
25

26 (2) NCRP or Cardiovascular and metabolic disease, South African Medical Research Council &  
27 University of Cape Town, Cape Town, South Africa  
28

29 (3) Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, Yaounde,  
30 Cameroon  
31  
32

33 (4) Department of Internal Medicine, Yaounde General Hospital , Cameroon  
34

35 (5) Department of Internal Medicine, Bafoussam Regional Hospital , Cameroon  
36  
37

38 (6) Department of Internal Medicine, Bamenda Military Hospital , North West Region, Cameroon  
39

40 **Correspondence to:** Dr Anastase Dzudie, MD; FESC. Douala General Hospital; PO Box 4856,  
41 Douala General Hospital, Douala – Cameroon, Tel: +(237)79617981; Fax: +(237)33370146; email:  
42 [aitdzudie@yahoo.com](mailto:aitdzudie@yahoo.com)  
43  
44  
45  
46  
47

48 Tables #4; Figures #1.  
49

50 Word count: Abstract (265); Main text excluding reference, figure legend and references (3720)  
51  
52  
53

54 \* Members list in the appendix section  
55  
56  
57  
58  
59  
60



## Abstract

**Objectives.** Hypertension has been established as a major public health problem in Africa, but its specific contributions to disease burden are still incompletely understood. We **quantified** **report** the **burden-prevalence** and determinants of hypertension, detection, treatment and control rates among adults in major cities in Cameroon.

**Design.** Cross-sectional study

**Settings.** Community-based multicenter study in major cities in Cameroon

**Participants.** Participants were self-selected urban dwellers from the Center, Littoral, North-West and West Regions, who attended on May 17th 2011 a screening campaign advertised through mass media.

**Primary and secondary outcomes measures.** Hypertension defined as systolic (and/or diastolic) blood pressure  $\geq 140$  (90) mmHg, or ongoing blood pressure (BP) lowering medications.

**Results.** In all, 2120 participants (1003 women) were included. Among them, 1007 (prevalence rate 47.5%) had hypertension, including 319 (awareness rate 31.7%) who were aware of their status. The prevalence of hypertension increased with age overall and by sex and region. Among aware hypertensive participants, 191 (treatment rate 59.9%) were on regular BP lowering medication, and among those treated, 47 (controlled rate 24.6%) were at target BP levels (i.e. systolic (and diastolic) BP  $<140$  (90) mmHg). In multivariable logistic regressions analysis, male gender, advanced age, parental history of hypertension, diabetes mellitus, elevated waist, and elevated body mass index (BMI) were the significant predictors of hypertension. Likewise, male gender, high BMI and physical inactivity were associated with poor control.

**Conclusions.** High prevalence of hypertension with low awareness, treatment and control were found in this urban population; these findings are significant and alarming with



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

consideration to the various improvements in the access to healthcare and the continuing efforts to educate communities over the past decades.

Word count - 265

**Key Words:** Hypertension, prevalence, awareness, treatment, control, Cameroon, Africa

For peer review only

## Article summary

### Article focus

- This article quantified the burden and determinants of hypertension, detection, treatment and control rates among self-selected adults in major cities in Cameroon, central Africa

### Key messages

- The prevalence of hypertension was very high in this population, coupled with low detection, treatment and control rates.
- Age, gender and excess weight were the main drivers of the high prevalence, while the coincidence of classical cardiovascular risk factors was associated with poor control.

### Strengths and limitations of this study

- Major strengths of this study include the large sample, the multicenter nature, the rigorous data collection on a range of determinants and provision of standardized prevalence figures.
- Limitations include the selection of participants, and hypertension diagnosis based on blood pressure measurement during a single encounter.

## Introduction

Hypertension has been established as a major public health problem worldwide.[1] Several published studies suggest that hypertension is the commonest modifiable risk factor for stroke, congestive heart failure and kidney failure[2-5] in the sub-Saharan African (SSA) region. It is a major contributor to overall mortality risk in adults in the region.[6] Hypertension also seems to be more common in urban than rural population[7] of the SSA region.

Specific risks associated with various blood pressure (BP) readings have largely been established for populations in many parts of the developed world but this is not the case for countries of the developing world including the SSA region. There is considerable evidence that long-term BP lowering to what is considered either normal or optimal levels results in several significant and important health benefits.[8] When established norms for ideal or optimal BP are applied to SSA populations, it becomes very evident that the vast majority of eligible patients do not enjoy the benefits of BP lowering therapies, either because of under-diagnosis or the many other barriers to BP lowering medications prescription, access and compliance in this setting.[1 2] As a case in point, a survey in Cameroon about eight years ago found that only 23% of all individuals with hypertension at the community level were aware of their status.[9] Moreover, only 46% of those aware (11% of all those with hypertension) were on treatment, among whom only 19% (2% of all those with hypertension) achieved expected target BP levels.[9]

There is also evidence that SSA is undergoing very rapid transitions characterized by increasing urbanization, including the adoption of unhealthy lifestyles.[10 11] These transitions are paralleled by changes in the profile of chronic disease risk factors including

1  
2  
3 blood pressure.[7] Recently there has been increasing awareness of the threat that the  
4  
5 looming chronic diseases pose to the health of the population in the Region at different  
6  
7 levels.[12] This increasing awareness has catalyzed initiatives aimed at improving access to  
8  
9 detection and care of chronic diseases including hypertension[13] in many countries of the  
10  
11 region. The pace of the above mutations suggests that, data on the burden of hypertension,  
12  
13 must be updated regularly, in order to provide the reliability needed in drawing-up health  
14  
15 service and policy solutions.  
16  
17

18  
19 The aim of this study was to assess the prevalence and determinants of hypertension, and  
20  
21 including the detection, treatment and control rates, as well as the variability by region and  
22  
23 gender in four major cities of Cameroon.  
24  
25

## 26 27 **Material and methods**

### 28 29 *Study population and settings*

30  
31 This was a cross-sectional population-based study conducted in the regional capitals of the  
32  
33 Centre (Yaounde), Littoral (Douala), North-West (Bamenda) and West (Bafoussam)  
34  
35 administrative regions (out of a total of ten) of Cameroon. According to the Cameroon  
36  
37 National Institute of Statistics,[14] the four participating regions had a total population of 9.98  
38  
39 million in 2010 (51% of the country's total population: 19.41 millions). In this same year,  
40  
41 57.5% of the national population was aged 15 years and above, and about 52% resided in  
42  
43 what was defined as an urban area.[14] During three consecutive weeks leading to the  
44  
45 specified day of the survey, daily announcements were made through radio and television,  
46  
47 inviting all interested adults (or individuals aged 15 years and above) to report to any of the  
48  
49 screening sites in participating cities. Such explanation included advice on the importance of  
50  
51 measuring and knowing one's blood pressure under the slogan "I know my blood pressure.  
52  
53 And you?". Announcements were also made in churches and market places. The study  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 protocol was approved by the Cameroon National Ethics Committee and signed informed  
4  
5 consent obtained from each participant.  
6

### 7 *Data collection*

8  
9  
10 The screening was conducted by trained medical personnel, simultaneously in the four cities  
11  
12 on the specified date of May 17<sup>th</sup> 2011. All participants were subjected to a face-to-face  
13  
14 interview during which data were collected (using a standardized questionnaire) on  
15  
16 demographics, smoking habits and alcohol consumption, physical activity, parental history of  
17  
18 hypertension, personal medical history (where the diagnosis was made by a physician) of  
19  
20 hypertension including drug treatment, diabetes mellitus, gout and dyslipidemia. The  
21  
22 physical examination included blood pressure (BP) and anthropometric measurements. BP  
23  
24 (systolic and diastolic) was measured using a standardized protocol with the participant in a  
25  
26 seated position, and after at least 10 minutes rest. Participants with evidence of recent (less  
27  
28 than 30 minutes) alcohol intake or smoking were invited to a 30 minutes rest before BP  
29  
30 measurement. BP measurements were performed on the right arm using automated  
31  
32 sphygmomanometers (OMRON M3 HEM-7200-E Omron Matsusaka Co Ltd, Japan). Special  
33  
34 attention was given to the use of appropriate cuff sizes (13×23 cm or 16×30 cm). Weight (to  
35  
36 the nearest 0.5 kg) was measured with the use of an automated scale. Participants were  
37  
38 permitted to keep on light clothing. Height (in meters to the nearest 0.5cm) was measured  
39  
40 using a wooden platform and a height rule. Body mass index (BMI in kg/m<sup>2</sup>) was calculated  
41  
42 as weight (kg)/[height (m) X height (m)]. Waist circumference was measured midway  
43  
44 between the iliac crest and the lower rib margin and the hip circumference was measured at  
45  
46 the intertrochanteric level. Waist-to-hip ratio (WHR) was calculated as waist (cm)/Hip (cm)  
47  
48 circumferences.  
49  
50  
51  
52  
53

### 54 *Definitions*

1  
2  
3 Respondents were classified as hypertensive if they had a systolic (and/or diastolic) BP of 140  
4 (90) mmHg or higher, or if they were on blood pressure lowering medications over the last 15  
5 consecutive days. Participants with hypertension were considered to be aware of their status if  
6 they answered 'yes' to the question 'have you ever been told by a doctor or health  
7 professional that you had hypertension?'. Treatment of high BP was defined by the use of BP  
8 lowering medications. Hypertension was considered to be controlled among treated  
9 individuals when systolic (and diastolic) SBP was < 140 (90) mmHg or <130 (80) mmHg in  
10 individuals with diabetes. Waist circumference >94 cm in men or 80 cm in women was  
11 considered to be high. Excessive alcohol consumption was based on intake of either more  
12 than three (two for women) standard glasses of wine per day or more than ten (five for  
13 women) local beers (1 local beer contains 28 g of alcohol) per week. Traditional alcohol  
14 beverages were not assessed. Participants who smoked at least one cigarette per day at the  
15 time of the study were classified as current smokers, and those who have smoked for at least 3  
16 years in the past, but had stopped by the time of the study were classified as former smokers.  
17 Regular non-work related physical activity was considered in participants reporting at least 30  
18 min of intense physical activity, once a week or more.

### 38 ***Handling of participants with high blood pressure***

39  
40 Participants with hypertension (known or screened-detected) received on-site medical  
41 counseling and were referred back to their attending physician (known cases), or to specialists  
42 within the vicinity of the participant's residential area for workup and long-term management.  
43 Few participants with excessively high BP with or without suspected acute target organ  
44 damage were immediately referred to emergency departments for appropriate care.

### 51 ***Statistical analysis***

52 Data analysis used the Statistical Package for Social Sciences (SPSS Inc, Chicago, IL) version  
53 17.0 software. Results are summarized as count and percentages for qualitative variables and  
54  
55  
56  
57

1  
2  
3 mean and standard deviation (SD) for quantitative variables. Age-adjusted prevalence was  
4  
5 calculated using the Cameroon National population's age structure in 2010 as standard  
6  
7 population.[15] Direct standardization methods was applied.[16] Group comparisons used chi  
8  
9 square tests and equivalents for qualitative variables and Student t-test, analysis of the  
10  
11 variance (ANOVA) for quantitative variables. Logistic regressions analyses were used to  
12  
13 investigate potential determinants of prevalent hypertension and control. A p-value<0.05 was  
14  
15 used to characterize statistically significant results.

### 16 17 18 *Sensitivity analysis*

19  
20 The main analyses were based on a single blood pressure measurement. To assess the  
21  
22 potential effects of 'regression to the mean' phenomenon on the prevalence of hypertension, a  
23  
24 sensitivity analysis was conducted among participants with a raised initial blood pressure  
25  
26 (SBP/DBP $\geq$ 140/80 mmHg) and who had their blood pressure taken a second time on the  
27  
28 same day. This analysis was based on the average of the first and second measurements.  
29  
30  
31  
32  
33

## 34 **Results**

### 35 36 *The study population*

37  
38 Two thousand one hundred and twenty eligible participants reported for screening in the four  
39  
40 regions including 649 (30.6%) in the Centre, 1167 (54.1%) in the Littoral and 304 (14.3%) in  
41  
42 the West and North West regions. Their overall profile including gender and region is  
43  
44 summarized in Table 1. Participants included 1003 women (47.3%). Compared with men,  
45  
46 women had similar age (43 vs. 44 years, p=0.19), similar waist circumference (93 vs. 93 cm,  
47  
48 p=0.80), and similar history of diabetes mellitus, dyslipidemia and gout (all p $\geq$ 0.07, Table 1).  
49  
50 They were likely to have higher body mass index, higher prevalence of parental history of  
51  
52 hypertension, lower systolic and diastolic blood pressure, and were less likely to be either a  
53  
54 smoker or alcohol drinker and physically active (all p $\leq$ 0.001. Table 1). With a few  
55  
56  
57  
58  
59  
60

1  
2  
3 exceptions, the above pattern was consistent within participating regions. However, the small  
4  
5 numbers of recruits in some subgroups translated into non-significant men/women differences  
6  
7 (Table 1). With the exception of smoking ( $p=0.07$ ), differences were also apparent in the  
8  
9 baseline profile across Regions (all  $p\leq 0.01$  for differences across regions).

### 10 11 ***Blood pressure profile***

12  
13 Mean systolic and diastolic BP (SD) at the total population level (men vs. women) was 139  
14  
15 (25) vs. 134 (28) mmHg ( $p<0.001$ ), and 83 (17) vs. 80 (17) mmHg ( $p=0.001$ ). Mean systolic  
16  
17 BP steadily increased with increasing age in men and women and across participating regions.  
18  
19 Diastolic BP also increased with increasing age, but only up to the fourth and fifth decade of  
20  
21 age, after which the pressure stabilized. This was observed in men and women and across  
22  
23 regions (Figure 1).  
24  
25

26  
27 The distribution of participants by BP categories according to the 2003 ESH/ESC  
28  
29 classification [17] was examined by sex and regions, overall and by age groups. An optimal  
30  
31 BP (systolic BP<120 and diastolic BP<80 mmHg) was observed in 21.6% of men and 29.6%  
32  
33 of women. The prevalence of optimal or normal BP decreased with increasing age in men and  
34  
35 women (all  $p\leq 0.001$  for linear trend). Conversely, with the exception of grade 1 hypertension  
36  
37 (both  $p\geq 0.09$  for linearity) and high normal BP in women only ( $p=0.13$ ), the prevalence of all  
38  
39 other BP categories linearly increased with increasing age (all  $p<0.001$  for linear trend).  
40  
41

42  
43 Similar trends were also observed across participating regions. However, the distribution of  
44  
45 participants across BP categories varied significantly by region ( $p<0.0001$ )  
46

### 47 ***Prevalence of hypertension, and awareness and control rates***

48  
49 The prevalence of hypertension was 47.5% overall, and 50.1% and 44.6% in men and women  
50  
51 respectively ( $p<0.001$ ), Table 3. As expected, prevalence rate sharply increased with age  
52  
53 down from 31.7% (men) and 20.2% (women) in the age group <35 years, up to 77.6% (men)  
54  
55 and 75.2% (women) in the age group 55 years and above (Table 3). Awareness rate increased  
56  
57



1  
2  
3 with increasing age in men and women (both  $p < 0.001$  for linear trend). Among participants  
4  
5 with hypertension, 24.6% in men and 40.5% in women were aware of their condition, and  
6  
7 those remaining were newly diagnosed. Of those aware of their hypertensive status, 57.9% in  
8  
9 men and 61.3% in women were on BP lowering medications, similarly across age groups in  
10  
11 men ( $p = 0.53$  for linear trend), and with a modest linearly increasing trend with age in women  
12  
13 ( $p = 0.03$ , Table 3). Among treated patients, 27.5% in men and 38.7% in women were at target  
14  
15 BP levels [i.e. systolic (and diastolic) BP  $< 140$  (90) mmHg], and similarly across age strata  
16  
17 (both  $p \geq 0.06$  for linear trend). Control rate was about 10% lower when the target BP level of  
18  
19  $< 130$  (80) was applied to participants with diabetes (Table 3).  
20  
21

22  
23 Crude prevalence of hypertension, awareness and treatment varied significantly across  
24  
25 participating regions (all  $p < 0.001$ ). The highest crude prevalence (53.6%) was observed in the  
26  
27 Littoral region, while the highest crude awareness (60.9%) and treatment rates (49.0%) were  
28  
29 observed in provinces other than Centre ad Littoral (Table 3). Control rate was also higher in  
30  
31 those two region when the threshold level of 140/90 mmHg was applied to all treatments  
32  
33 participants ( $p < 0.001$ ). This difference however was non-significant when the threshold of  
34  
35 130/80 mmHg was applied to participants with diabetes. The age trends in prevalence,  
36  
37 awareness, treatment and control across regions were largely similar to those observed in men  
38  
39 and women (Table 3).  
40  
41

#### 42 43 *Predictors of hypertension and control among urban dwellers*

44  
45 Unadjusted and adjusted odd ratios and 95% confidence intervals for Determinants the  
46  
47 association of prevalent hypertension with potential predictors are shown in Table 3. In  
48  
49 multivariable logistic regression models adjusted for age, sex, parental history of  
50  
51 hypertension, body mass index and region, the significant predictors of prevalent hypertension  
52  
53 were ~~In unadjusted logistic regressions analysis~~, male ~~gender~~sex, increasing age, Region,  
54  
55 parental history of hypertension, personal history of diabetes, ~~gout, excessive alcohol~~  
56  
57  
58  
59  
60

1  
2  
3 ~~consumption~~, high BMI and high waist circumference ~~were associated with prevalent~~  
4 ~~hypertension~~ (Table 3). ~~In multivariable adjusted models, history of gout and excessive~~  
5 ~~alcohol consumption were no longer associated with prevalent hypertension. Table 4 shows~~  
6 ~~the crude and adjusted odds ratios (ORs) of hypertension control among treated patients. In~~  
7 ~~multivariable models with similar level of adjustment (Table 4),~~ Male sex, high BMI  
8 and physical inactivity were associated with poor control of hypertension, while being from  
9 Regions other than Centre or Littoral was associated with good control among treated patients  
10 (Table 54).

### 21 *Sensitivity analysis*

22 Among participants with newly diagnosed hypertension based on the first blood pressure  
23 measurement (688 participants), 537 (78.0%) had a valid second measurement. Their mean  
24 blood pressure (SD) was 159.4 (19.0) for systolic and 94.4 (14.2) mmHg for diastolic based  
25 on the first measurement. Equivalent were 154.5 (19.0) and 93.0 (13.1) mmHg based on the  
26 average of the two measurements. Of the 537 participants 461 (85.8%) had hypertension  
27 (systolic/diastolic blood pressure  $\geq$  140/90 mmHg) using the average of the two blood  
28 pressure measurements.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **Discussion**

41 In this self-selected urban adult population study from Cameroon, we found a high  
42 prevalence of hypertension, coupled with low detection, treatment and control rates. The high  
43 prevalence was largely driven by age, as well as by gender and excess weight. However,  
44 among those diagnosed and on treatment, control rate was similar across age groups, although  
45 there were suggestions of regional differences, possibly reflecting underlying differences in the  
46 access to healthcare and health resources utilization. Our study provides comparative data  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 across major cities in Cameroon and suggests findings compatible with previously reported  
4  
5 high prevalence rates of hypertension in the country.  
6

### 7 ***Prevalence of hypertension***

8  
9 During the last ten years, at least two prevalence studies on hypertension have been reported  
10  
11 in urban Cameroon, applying similar definitions for hypertension, but different sampling  
12  
13 strategies.[7 9 18] The age-adjusted prevalence of hypertension in the current study is higher  
14  
15 than that reported by Kamadjeu[9] in 2003, but similar to the findings of Fezeu[7] around that  
16  
17 same time. This balance of findings would tend to suggest that the prevalence of hypertension  
18  
19 in this setting is either stabilizing or growing at a much slower pace than previously  
20  
21 reported.[7]  
22

23  
24 Elsewhere, available data on hypertension in Africa are from very heterogeneous studies, and  
25  
26 therefore offer less opportunities for reliable comparison.[3] Such heterogeneities include  
27  
28 differences in sampling methods and study settings (predominance of hospital based study),  
29  
30 the type of participants enrolled, the measurements of blood pressure and definition of  
31  
32 hypertension, and the time period when the study was conducted.[19] Reliable, large-scale,  
33  
34 population-based data on high blood pressure in sub-Saharan Africa are very limited; however  
35  
36 available recent studies provide findings that demonstrate similarly high prevalence of  
37  
38 hypertension in urban settings.[20-22] Moreover, those findings already tend to be similar to  
39  
40 those reported in the developed world,[23 24] therefore, raising serious concerns given the  
41  
42 young age of clinical onset of hypertension in Africa.  
43  
44  
45  
46

### 47 ***Awareness, treatment and control of hypertension***

48  
49 In Cameroon, over the last ten years, there have been a number of initiatives aimed at scaling  
50  
51 up the fight against chronic diseases in general, and hypertension and diabetes mellitus in  
52  
53 particular,[25] including: 1) the adoption of a National Strategy for hypertension and  
54  
55 diabetes;[25] and 2) the development of training and task-shifting programmes to improve  
56  
57  
58  
59  
60

1  
2  
3 detection and management at primary care level.[13 26] Findings from our study would tend  
4  
5 to suggest that the good will contained in the National Strategy has perhaps not yet been fully  
6  
7 translated into actions with sizable positive effects on the health of the population. For  
8  
9 instance, the Strategy aimed to improve level of risk factors by 25% and achieve optimal  
10  
11 control among those diagnosed with the condition.[25] However, we found awareness,  
12  
13 treatment and control rates which were within the range of those previous reported in  
14  
15 Cameroon prior to the adoption of the Strategy[7 9] and recently in other settings in  
16  
17 Africa.[20 22 25] The low awareness rate if confirmed, could be blamed on low detection  
18  
19 activity and accordingly non-optimal performance of the National strategy. It is also possible  
20  
21 that many participants already diagnosed with hypertension, and perhaps on treatment and  
22  
23 controlled on such treatment, did not feel the need to attend the screening campaign again.  
24  
25 This would have the undesirable effect of biasing our estimates by providing much lower than  
26  
27 the true figures. It is also possible that those with known and treated condition instead turned  
28  
29 out in higher number to use the campaign as an opportunity for their health checkup free of  
30  
31 charge. Our stratified analyses suggest that this mix could vary substantially by participating  
32  
33 centers. In general however, low awareness of hypertension has been reported as a global  
34  
35 phenomenon,[27] although the magnitude may be less important in the developed world[23  
36  
37 28]. In the USA for instance, awareness of hypertension is as higher as 76%,[28] reflecting  
38  
39 the success achieved by a coordinated policy to detect individuals with higher-than-optimal  
40  
41 blood pressure levels.  
42  
43  
44  
45  
46

47 The low treatment and control rates in our study reflect the interplay between many factors  
48  
49 which were not directly captured by the current study. These include both patient-level,  
50  
51 healthcare provider level and health system level factors. Indeed, patients are expected to be  
52  
53 treated and controlled only if they can access appropriate health services, receive adequate  
54  
55 advice and prescriptions, and subsequently afford and adhere to those prescriptions.  
56  
57  
58  
59  
60

1  
2  
3 Accessibility to health care facility has likely improved in urban settings in Cameroon in  
4 recent years. However the physician-to-population ratio, just like in many other countries in  
5 the region, is still very low[29] and may explain the low awareness and treatment gaps.  
6  
7

8  
9 Affordability of the cost of care also remains a major barrier in the study setting where out-of-  
10 pocket spending is the main source of funding for healthcare costs. Adherence to prescribed  
11 medications is another patient-level determinant of risk factor control not investigated in the  
12 present study. Studies in Africa have shown that non-adherence to treatment and follow-up  
13 for hypertension was very common.[30-32] In one intervention study in Cameroon for  
14 instance, just about half of participants were still in the programme at 1-year of follow-up.[31]  
15  
16  
17  
18  
19  
20  
21

### 22 ***Potential limitations and strengths of our study***

23  
24 The present study has some limitations. Participants were self-selected and may therefore not  
25 necessarily be representative of the general population in participating cities. Access to mass  
26 media (radio and television) is almost universal in major cities in the countries, and there is  
27 therefore no suggestion that advertisement of the campaign would have selectively reached  
28 certain portions of the population. It remains however; that participants in the study could still  
29 differ from the general population by being more or less health conscious, and having less  
30 severe disease for example, which could affect some parameters in the study. The study used  
31 a cross-sectional design, which precludes any causality inference. Diagnosis of hypertension  
32 was based on blood pressure measurements during a single encounter, which is at variant with  
33 guidelines recommendations for hypertension diagnosis using two measurements recorded on  
34 three separate occasions.[17] This may have overestimated the prevalence of hypertension  
35 and underestimated the level of blood pressure control. This however, would not affect  
36 comparisons with previous epidemiological studies that have used similar measurement  
37 methodology. Diagnosis of hypertension among those with no history of hypertension in our  
38 study was based on a single blood pressure measurement. Our sensitivity analysis suggests  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 that this approach could inflated the crude prevalence by about 5.4% and 4.6% among those  
4  
5 not known to have hypertension prior to the survey and at the total population level  
6  
7 respectively. Nevertheless, even after accounting for this possible effect, our estimates would  
8  
9 still be within sampling variation of the figures previously reported in this setting. It is also of  
10  
11 note that no participant received a definitive diagnosis of hypertension as the result of taking  
12  
13 part in this study. Those with elevated blood pressure levels were instead referred to health  
14  
15 care facilities for further evaluation. The strengths of this study include the large sample of  
16  
17 the general population and, the rigorous collection of various lifestyle factors, medical data  
18  
19 and blood pressure measurements by trained staff according to standardized protocols, the  
20  
21 adequate standardization of prevalence and allowing comparisons with other African  
22  
23 countries. In addition, our sampling approach provides evidence that simple announcements  
24  
25 through mass media can attract from the community a large number of individual at risk of  
26  
27 undiagnosed hypertension.  
28  
29  
30

### 31 **Conclusions**

32  
33  
34 In conclusion, our study ~~has provides provided~~ findings ~~suggesting that are in line with~~ the  
35  
36 high prevalence of hypertension previously reported in urban settings in Africa. The study  
37  
38 further suggests that Detection efforts to detect, and treatment and control effortsto the targets  
39  
40 those with the disease are ~~likely~~ still ~~well~~ below optimal. This raises serious concerns about  
41  
42 the prospects of having to care very soon for both patients with higher-than-optimal blood  
43  
44 pressure and many more with target organ lesions subsequent to longstanding hypertension.  
45  
46 There are already some indications that the burden of stroke, end-stage renal disease and heart  
47  
48 failure related to hypertension is growing in the country and the region.[2 6 33]  
49  
50

### 51 **Perspectives**

52  
53  
54 The low awareness, treatment and control rates of hypertension in this potentially health  
55  
56 conscious urban sub-Saharan population invite innovative approaches to improve prevention,  
57  
58  
59  
60

1  
2  
3 detection, treatment of hypertension beyond the traditional healthcare facilities based  
4  
5 approaches which are currently in force in many countries in the region.  
6  
7  
8  
9

10  
11  
12 **Declaration of competing interest.** None for all authors.  
13

14 **Author contribution.** Dzudie and Kengne had full access to all of the data in the study and  
15  
16 takes responsibility for the integrity of the data and the accuracy of the data analysis.  
17  
18

19 Study concept and design: Dzudie, Kengne, Muna, Ngu, Kingue.  
20

21  
22 Acquisition of data: Ba, Menanga, Kouam Kouam, Abah, Monkam, Biholong, Mintom,  
23  
24 Kamdem, Djomou, Njebet, Ouambo, Luma,  
25  
26

27 Analysis and interpretation: Dzudie, Kengne, Muna  
28  
29

30 Drafting of the manuscript: Dzudie, Kengne, Muna  
31  
32

33 Critical revision of the manuscript for important intellectual content: all co-authors  
34  
35  
36  
37  
38

### 39 **Acknowledgements**

40 The authors would like to express their gratitude to the following bodies and individuals for  
41  
42 their contribution to the success of this study: 1) The Cameroon Ministry of public health for  
43  
44 providing the blood pressure devices and health staff; 2) The executive committee and  
45  
46 members of the Cameroon Cardiac Society for their support for data collection; 3) Servier  
47  
48 Pharma Cameroon for a financial contribution to support data processing and drafting of the  
49  
50 manuscript; 4) All specialist physicians, enthusiastic general practitioners, medical students  
51  
52 and nurses involved in data collection; and 5) All those who helped at the different stages of  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 the project and the fellow Cameroonians who volunteered across the four participating cities  
4  
5 to take part in the study.  
6  
7

8 **Data sharing statement:** No additional data available  
9

## 10 **Appendix 1**

11  
12 Cameroon Cardiac Society (CCS) investigators group:  
13

- 14  
15 (1) Douala: Anastase Dzudie, Hamadou Ba, Henri Roger Ngote, Christian Biholong,  
16  
17 Félicité Kamdem, Armel Djomou, Jules Njebet, Cyrille Ouambo, Roger Mboulley  
18  
19 Kotto, Barbara Bouellet Abeng, Marielle Epacka Ewane Lobe and Yves Monkam.  
20  
21 (2) Yaounde : Alain Menanga, Pierre Mintom, Euloge Yiagnigni, Mérimée Ouankou,  
22  
23 Christophe Nouedoui, Pierre Ndobu, Marie Ntep, Monique Kenfack, Sylvie Ndongu,  
24  
25 Martine Tchuem, Edvine Wawo, Walinjom F.T. Muna, Katleen Ngu Blackett and  
26  
27 Samuel Kingue.  
28  
29 (3) Bafoussam: Charles Kouam Kouam  
30  
31 (4) Bamenda: Joseph Abah.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

## 46 **References**

- 47  
48  
49 1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of  
50  
51 worldwide data. *Lancet* 2005;365:217-23.  
52  
53 2. Kengne AP, Anderson CS. The neglected burden of stroke in Sub-Saharan Africa. *Int J*  
54  
55 *Stroke* 2006;1:180-90.  
56  
57  
58  
59  
60



- 1  
2  
3 3. Addo J, Smeeth L, Leon DA. Hypertension in sub-saharan Africa: a systematic review.  
4  
5 *Hypertension* 2007;50:1012-8.  
6
- 7 4. Kengne AP, Amoah AG, Mbanya JC. Cardiovascular complications of diabetes mellitus in  
8  
9 sub-Saharan Africa. *Circulation* 2005;112:3592-601.  
10
- 11 5. Damasceno A, Cotter G, Dzudie A, et al. Heart failure in sub-saharan Africa: time for  
12  
13 action. *J Am Coll Cardiol* 2007;50:1688-93.  
14
- 15 6. Kengne AP, Awah PK. Classical cardiovascular risk factors and all-cause mortality in rural  
16  
17 Cameroon. *Qjm* 2009;doi:10.1093/qjmed/hcn175.  
18
- 19 7. Fezeu L, Kengne AP, Balkau B, et al. Ten-year change in blood pressure levels and  
20  
21 prevalence of hypertension in urban and rural Cameroon. *J Epidemiol Community*  
22  
23 *Health* 2010;64:360-5.  
24
- 25 8. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular  
26  
27 events: results of prospectively-designed overviews of randomised trials. *Lancet*  
28  
29 2003;362:1527-35.  
30
- 31 9. Kamadjeu RM, Edwards R, Atanga JS, et al. Prevalence, awareness and management of  
32  
33 hypertension in Cameroon: findings of the 2003 Cameroon Burden of Diabetes  
34  
35 Baseline Survey. *J Hum Hypertens* 2006;20:91-2.  
36
- 37 10. Leon DA. Cities, urbanization and health. *Int J Epidemiol* 2008;37:4-8.  
38
- 39 11. Popkin BM. Global nutrition dynamics: the world is shifting rapidly toward a diet linked  
40  
41 with noncommunicable diseases. *Am J Clin Nutr* 2006;84:289-98.  
42
- 43 12. de-Graft Aikins A, Unwin N, Agyemang C, et al. Tackling Africa's chronic disease  
44  
45 burden: from the local to the global. *Globalization and health* 2010;6:5.  
46
- 47 13. Lekoubou A, Awah P, Fezeu L, et al. Hypertension, diabetes mellitus and task shifting in  
48  
49 their management in sub-Saharan Africa. *Int J Environ Res Public Health* 2010;7:353-  
50  
51 63.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 14. Cameroon's National Institute of Statistics. Statistical Yearbook 2010, 2011:39-52.
- 4  
5 15. Cameroon's National Institute of Statistics. Population du Cameroun en 2010, 2011.
- 6  
7 16. Woodward M, editor. *Epidemiology: study design and data analysis*. Second ed. New  
8  
9 York: Chapman & Hall/CRC, 2005.
- 10  
11 17. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of  
12  
13 Arterial Hypertension: The Task Force for the Management of Arterial Hypertension  
14  
15 of the European Society of Hypertension (ESH) and of the European Society of  
16  
17 Cardiology (ESC). *J Hypertens* 2007;25:1105-87.
- 18  
19 18. Kengne AP, Awah KP, Fezeu L, et al. The burden of high blood pressure and related risk  
20  
21 factors in urban sub-Saharan Africa: Evidences from Douala in Cameroon. *African*  
22  
23 *Health Sciences* 2007;7:38-44.
- 24  
25 19. Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic  
26  
27 blood pressure since 1980: systematic analysis of health examination surveys and  
28  
29 epidemiological studies with 786 country-years and 5.4 million participants. *Lancet*  
30  
31 2011;377:568-77.
- 32  
33 20. Jenson A, Omar AL, Omar MA, et al. Assessment of hypertension control in a district of  
34  
35 Mombasa, Kenya. *Glob Public Health* 2011;6:293-306.
- 36  
37 21. Ulasi, II, Ijoma CK, Onodugo OD. A community-based study of hypertension and cardio-  
38  
39 metabolic syndrome in semi-urban and rural communities in Nigeria. *BMC Health*  
40  
41 *Serv Res* 2010;10:71.
- 42  
43 22. Damasceno A, Azevedo A, Silva-Matos C, et al. Hypertension prevalence, awareness,  
44  
45 treatment, and control in mozambique: urban/rural gap during epidemiological  
46  
47 transition. *Hypertension* 2009;54:77-83.
- 48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 23. Wagner A, Sadoun A, Dallongeville J, et al. High blood pressure prevalence and control  
4  
5 in a middle-aged French population and their associated factors: the MONA LISA  
6  
7 study. *J Hypertens* 2011;29:43-50.  
8  
9  
10 24. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood  
11  
12 pressure levels in 6 European countries, Canada, and the United States. *Jama*  
13  
14 2003;289:2363-9.  
15  
16 25. Njamnshi AK, Bella Hiag A, Mbanya JC. From research to policy: the development of a  
17  
18 national diabetes programme in Cameroon. *Diabetes Voice* 2006;55:18-21.  
19  
20  
21 26. Kengne AP, Sobngwi E, Fezeu L, et al. Setting-up nurse-led pilot clinics for the  
22  
23 management of non-communicable diseases at primary health care level in resource-  
24  
25 limited settings of Africa *PAMJ* 2009;3:10.  
26  
27  
28 27. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the  
29  
30 community: is the 'rule of halves' still valid? *J Hum Hypertens* 1997;11:213-20.  
31  
32 28. Cheung BM, Ong KL, Man YB, et al. Prevalence, awareness, treatment, and control of  
33  
34 hypertension: United States National Health and Nutrition Examination Survey 2001-  
35  
36 2002. *J Clin Hypertens (Greenwich)* 2006;8:93-8.  
37  
38  
39 29. World Health Organisation. Task shifting to tackle health worker shortage. Geneva, 2007.  
40  
41 30. Kengne AP, Awah PK, Fezeu LL, et al. Primary health care for hypertension by nurses in  
42  
43 rural and urban sub-Saharan Africa. *J Clin Hypertens (Greenwich)* 2009;11:564-72.  
44  
45 31. Labhardt ND, Balo JR, Ndam M, et al. Improved retention rates with low-cost  
46  
47 interventions in hypertension and diabetes management in a rural African environment  
48  
49 of nurse-led care: a cluster-randomised trial. *Trop Med Int Health* 2011.  
50  
51 32. Dennison CR, Peer N, Steyn K, et al. Determinants of hypertension care and control  
52  
53 among peri-urban Black South Africans: the HiHi study. *Ethn Dis* 2007;17:484-91.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 33. Halle MP, Kengne AP, Ashuntantang G. Referral of patients with kidney impairment for  
4  
5 specialist care in a developing country of sub-Saharan Africa. *Ren Fail* 2009;31:341-8.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 **Legend for figures and tables**  
4

5  
6 **Figure 1:** Mean systolic and diastolic blood pressure by age groups for men (left panel) and  
7  
8 women (right panel).  
9

10  
11 **Figure 2 –** Blood pressure control among participants with hypertension according to the  
12  
13 number of cardiovascular risk factors.  
14

15  
16  
17 Risk factors considered were: overweight or obesity, high waist, current or past smoking,  
18  
19 physical inactivity, diagnosed diabetes, dyslipidemia. None of the 116 participants with none  
20  
21 of the risk factor had hypertension.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1 - General characteristics of the study population overall and by Region**

Characteristic	Regions									Overall			
	Centre			Littoral			North-West and West			p region	Men	Women	p
	Men	Women	P	Men	Women	P	Men	Women	p				
N	376	273		609	558		132	172		<0.001	1117	1003	
Mean age, yrs. (SD)	41 (12)	42 (14)	0.43	45 (13)	43 (14)	0.33	48 (14)	45 (14)	0.08	<0.001	44 (13)	43 (14)	0.19
Age groups, n			0.26			0.006			0.22	<0.001			0.01
<35 years	134	97		145	180		23	44			302	321	
35-44 years	99	57		154	108		32	40			285	205	
45-54 years	86	65		163	139		34	47			284	251	
≥55 years	57	54		146	131		43	41			246	226	
Mean BMI, kg/m <sup>2</sup> (SD)	26.2 (4.0)	27.2 (4.5)	0.002	26.9 (4.8)	29.0 (6.3)	<0.001	27.6 (5.0)	29.3 (5.4)	0.006	<0.001	26.7 (4.6)	28.6 (5.8)	<0.001
Waist girth, cm (SD)	96 (13)	94 (12)	0.04	91 (13)	91 (15)	0.31	95 (12)	97 (12)	0.15	<0.001	93 (13)	93 (14)	0.80
Mean SBP, mmHg (SD)	133 (22)	129 (24)	0.06	142 (26)	139 (30)	0.05	136 (25)	125 (25)	<0.001	<0.001	139 (25)	134 (28)	<0.001
Mean DBP, mmHg (SD)	77 (17)	77 (16)	0.98	85 (17)	82 (18)	0.001	85 (15)	79 (15)	0.001	<0.001	83 (17)	80 (17)	0.001
Parental hypertension, n	77	77	0.02	158	191	0.002	38	55	0.62	0.01	273	323	<0.001
History of diabetes, n	27	27	0.22	27	31	0.42	21	31	0.65	<0.001	75	89	0.07
History of dyslipidemia, n	1	0	>0.99	4	9	0.16	0	0	N/A	0.005	5	9	0.28
History of gout, n	0	1	0.42	13	9	0.53	1	0	0.43	<0.001	14	10	0.68
Physical activity, n	160	86	0.004	334	180	<0.001	82	104	0.77	<0.001	576	370	<0.001
Smoking, n			<0.001			<0.001			<0.001	0.07			<0.001
Never	320	267		500	540		113	170			933	977	
Former	21	26		43	7		4	0			68	12	
Current	35	36		66	11		15	2			116	14	
Excessive alcohol, n	85	17	<0.001	147	51	<0.001	51	32	<0.001	<0.001	283	100	<0.001

BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; SD, standard deviation

**Table 2 - Hypertension prevalence, awareness and control among self-selected urban dwellers in Cameroon**

Gender Region	Variable	Overall	Overall*	Age groups (years)				P-trend	
				<35	35-44	45-54	≥55		
Centre	Prevalence (%)	35.4	27.3 (23.3-31.3)	15.1	28.2	48.3	70.3	<0.001	
	SBP/DBP $\geq$ 140/90 mmHg or treatment (n)	230	230	35	44	73	78		
	Awareness (%)	30.4	12.5 (9.3-15.7)	0	22.7	31.5	47.4	<0.001	
	Among hypertensives (n)	70	70	0	10	23	37		
	Treatment (%)	61.4	21.9 (13.6-30.2)	NA	50.0	52.2	70.3	0.13	
	Among aware hypertensives (n)	43	43	NA	5	12	26		
	Control A (%)	25.6	6.7 (2.5-10.9)	NA	0	33.3	26.9	0.41	
	Among treated hypertensive (n)	11	11	NA	0	4	7		
	Control B (%)	25.6	6.7 (2.5-10.9)	NA	0	33.3	26.9	0.41	
	Among treated hypertensive (n)	11	11	NA	0	4	7		
	Littoral	Prevalence (%)	53.6	43.6 (39.2-48.0)	33.8	45.0	61.7	76.2	<0.001
		SBP/DBP $\geq$ 140/90 mmHg or treatment (n)	626	626	110	118	187	211	
Awareness (%)		25.1	15.1 (11.3-18.9)	9.1	11.9	25.1	40.8	<0.001	
Among hypertensives (n)		157	157	10	14	47	86		
Treatment (%)		49.0	38.7 (16.7-60.7)	30.0	57.1	46.8	51.2	0.42	
Among aware hypertensives (n)		77	77	3	8	22	44		
Control A (%)		18.2	26.8 (-13.7 to 67.3)	33.3	12.5	22.7	15.9	0.60	
Among treated hypertensive (n)		14	14	1	1	5	7		
Control B (%)		18.2	26.8 (-13.7 to 67.3)	33.3	12.5	22.7	15.9	0.60	
Among treated hypertensive (n)		14	14	1	1	5	7		
Others		Prevalence (%)	49.7	34.4 (26.6-42.2)	22.4	30.6	51.8	85.7	<0.001
		SBP/DBP $\geq$ 140/90 mmHg or treatment (n)	151	151	15	22	42	72	
	Awareness (%)	60.9	30.3 (17.7-42.9)	13.3	40.9	53.5	77.8	<0.001	
	Among hypertensives (n)	92	92	2	9	25	56		
	Treatment (%)	77.7	91.6 (5.6-178)	100	77.8	84.0	73.2	0.30	
	Among aware hypertensives	71	71	2	7	21	41		
	Control A (%)	31.0	12.9 (4.7-21.1)	0	42.9	14.3	39.0	0.22	
	Among treated hypertensive (n)	22	22	0	3	3	16		
	Control B (%)	56.3	51.5 (-9.7 to 113)	50.0	57.1	33.3	68.3	0.12	
	Among treated hypertensive (n)	40	40	1	4	7	28		
	Men	Prevalence (%)	50.1	41.3 (36.9-45.7)	31.7	38.9	57.2	77.6	<0.001
		SBP/DBP $\geq$ 140/90 mmHg or treatment (n)	560	560	96	111	162	191	
Awareness (%)		24.6	13.5 (10.0-17.0)	6.3	12.6	21.6	43.5	<0.001	
Among hypertensives (n)		138	138	6	14	35	83		
Treatment (%)		57.9	54.6 (19.3-89.9)	50	64.2	65.7	54.2	0.53	
Among aware hypertensives		80	80	3	9	23	45		
Control A (%)		18.8	28.2 (-12.0 to 68.6)	33.3	22.2	21.7	15.5	0.36	
Among treated hypertensive (n)		15	15	1	2	5	7		
Control B (%)		27.5	50.3 (-6.3 to 107)	66.6	22.2	26.1	26.7	0.49	
Among treated hypertensive (n)		22	22	2	2	6	12		
Women		Prevalence (%)	44.6	32.5 (28.8-36.2)	20.2	35.6	55.8	75.2	<0.001
		SBP/DBP $\geq$ 140/90 mmHg or treatment (n)	447	447	64	73	140	170	
	Awareness (%)	40.5	20.9 (15.6-26.2)	9.3	26.0	42.8	54.5	<0.001	
	Among hypertensives (n)	181	181	6	19	60	96		
	Treatment (%)	61.3	43.3 (13.9-72.7)	33.3	57.9	53.3	68.9	0.03	
	Among aware hypertensives	111	111	2	11	32	66		
	Control A (%)	28.8	8.0 (4.6-13.8)	0	18.1	21.8	34.8	0.08	
	Among treated hypertensive (n)	32	32	0	2	7	23		
	Control B (%)	38.7	12.8 (7.2-18.4)	0	2.7	31.3	45.5	0.06	
	Among treated hypertensive (n)	43	43	0	3	10	30		

Data are percentages with numerators below. Control A, blood pressure below 140/90 mmHg or 130/80 mmHg among diabetic patients; Control B, blood pressure below 140/90 mmHg among all participants. DBP, diastolic blood pressure; NA, not applicable SBP, systolic blood pressure.

\* Age standardized according to the 2010 Cameroon national population distribution.

**Table 3 - Crude and adjusted odds ratios for predictors of hypertension among self-selected urban dwellers in Cameroon.**

Variable	Category	Unadjusted odd ratios (95% CI)	p	Adjusted odd ratios (95% CI)*	p
Sex	Men	1.25 (1.05-1.48)	0.01	1.63 (1.34-2.00)	<0.001
Age	<35 years	1 (reference)	<0.001	1 (Reference)	<0.001
	35-44 yrs	1.74 (1.35-2.25)		1.32 (1.01-1.73)	
	45-54 yrs	3.75 (2.93-4.81)		2.81 (2.16-3.64)	
	≥55 yrs	9.41 (7.12-12.43)		8.27 (6.19-11.04)	
Region	Centre	1 (Reference)	<0.001	1 (Reference)	<0.001
	Littoral	2.11 (1.73-2.57)		1.89 (1.52-2.36)	
	Others	1.80 (1.36-2.37)		1.38 (1.01-1.89)	
Parental hypertension	Yes	1.47 (1.21-1.77)	<0.001	1.55(1.25-1.92)	<0.001
Diabetes mellitus	Yes	3.77 (2.61-5.44)	<0.001	2.63 (1.75-3.94)	<0.001
Dyslipidemia	Yes	2.00 (0.67-5.98)	0.22	1.55 (0.47-5.11)	0.47
Gout	Yes	3.36 (1.33-8.49)	0.01	1.70 (0.62-4.67)	0.30
Smoking	Never	1 (Reference)	0.11	1 (Reference)	0.62
	Former	1.59 (1.01-2.51)		0.96 (0.59-1.65)	
	Current	0.90 (0.63-1.29)		0.82 (0.54-1.22)	
Physical activity	No	0.90 (0.76-1.07)	0.23	1.13 (0.93-1.38)	0.21
Excessive alcohol	Yes	1.33 (1.06-1.66)	0.01	1.05 (0.81-1.36)	0.70
Body mass index	Normal	1 (Reference)	<0.001	1 (Reference)	<0.001
	Overweight	2.03 (1.65-2.50)		1.94 (1.54-2.45)	
	Obese	3.54 (2.83-4.43)		3.32 (2.57-4.29)	
High waist girth		2.12 (1.78-2.52)	<0.001	1.94 (1.51-2.48)	<0.001

\* age, sex, parental history of hypertension, body mass index and region adjusted; CI, confidence interval




**Table 4 - Crude and adjusted odds ratios for predictors of hypertension control among self-selected and treated hypertensives in four main cities of Cameroon.**

Variable	Category (%)	Unadjusted odd ratios (95% CI)	P	Adjusted odd ratios (95% CI)*	p
Sex	Men	0.59 (0.35-1.00)	0.05	0.47 (0.26-0.86)	0.01
Age	<35 years	1.00 (Reference)	0.87	1.00 (Reference)	0.63
	35-44 yrs	0.54 (0.12-2.32)		0.38 (0.07-1.99)	
	45-54 yrs	0.68 (0.19-2.45)		0.57 (0.13-2.41)	
	≥55 yrs	0.67 (0.19-2.34)		0.46 (0.11-1.88)	
Region	Centre	1.00 (Reference)	<0.001	1.00 (Reference)	<0.001
	Littoral	0.72 (0.35-1.50)		0.70 (0.33-1.52)	
	Others	3.36 (1.64-6.87)		3.50 (1.65-7.42)	
Parental hypertension	Yes	1.44 (0.87-2.40)	0.16	1.56 (0.89-2.75)	
Diabetes mellitus	Yes	2.73 (1.60-4.67)	<0.001	1.83 (0.98-3.39)	0.06
Dyslipidemia	Yes	0.74 (0.08-6.75)	0.79	1.30 (0.13-13.26)	0.83
Gout	Yes	NA (None)			
Smoking	Never	1.00 (Reference)	0.53	1.00 (Reference)	0.72
	Former	0.79 (0.21-2.89)		1.26 (0.30-5.34)	
	Current	0.32 (0.04-2.57)		0.44 (0.05-3.97)	
Physical activity	No	0.30 (0.17-0.56)	<0.001	0.36 (0.20-0.66)	0.001
	Excessive	0.59 (0.26-1.32)		0.64 (0.26-1.60)	
Body mass index	Normal	1.00 (Reference)	0.002	1.00 (Reference)	0.003
	Overweight	0.41 (0.22-0.77)		0.44 (0.22-0.90)	
	Obese	0.34 (0.18-0.66)		0.28 (0.14-0.59)	
High waist girth		0.86 (0.51-1.44)	0.56	0.77 (0.33-1.77)	0.54

\* age, sex, parental history of hypertension, body mass index and region adjusted; CI, confidence interval.

Figure 1:



1  
2  
3 **Manuscript ID bmjopen-2012-001217.R1 entitled "Prevalence, awareness, treatment**  
4 **and control of hypertension in a self-selected sub-Saharan African urban population: A**  
5 **cross-sectional study**  
6  
7

8  
9  
10 Dear Editor,

11  
12  
13  
14 We are grateful to the reviewers for their time and additional constructive comments on our  
15 manuscript.  
16

17  
18 Their new suggestions have been accounted for as shown in red colour (or with the track  
19 changes function) in the manuscript and further explained in the point-by-point response  
20 below. Each time our response includes material from the manuscript, it is indicated in *italic*  
21 and **in black** colour if such a material was already present in the original version of the  
22 manuscript or in **red colour** for new material.  
23  
24

25 We look forward to the outcome of your assessment.  
26

27  
28 Yours sincerely,  
29 Andre Pascal Kengne  
30 On behalf of the co-authors  
31  
32

33  
34  
35 **Reviewer(s)' Comments to Author:**  
36

37  
38 Reviewer: Dr Juliet Addo  
39 King College London  
40

41 There is no competing interests.

42 The authors have addressed the concerns raised in the previous review to a large extent. The  
43 points which cannot be addressed have been acknowledged. I am making a few points for  
44 modification below but do not need to see this again.  
45  
46  
47

48 **Our response:** We thank you for the appreciation  
49

50 The previous review have been addressed considerably. There are a few points that need  
51 attention.  
52

53 Firstly, the aims in the abstract have not been rephrased as done in the main text. They do  
54 mention that they will quantify the burden of hypertension.  
55

56  
57 **Our response:** We have changed the wording. The sentence now reads:  
58  
59  
60

1  
2  
3  
4 “We report the prevalence and determinants of hypertension, detection, treatment and  
5 control rates among adults in major cities in Cameroon.”  
6  
7

8 In the results section on page 10, there is the mention of optimal BP. This needs to be  
9 defined.  
10

11 **Our response:** This is based on the ESC 2007 guideline definition. We have now provided  
12 the definition. The relevant sentence reads:  
13

14  
15 “An optimal BP (systolic BP<120 and diastolic BP<80 mmHg) was observed in 21.6% of  
16 men and 29.6% of women.”  
17  
18

19 Results: The reporting of regression analyses from Tables 4 and 5 should focus on the  
20 adjusted values as these are the interesting bits not the unadjusted.  
21  
22

23 **Our response:** we have modified the section which now reads:  
24  
25

26 “Unadjusted and adjusted odd ratios and 95% confidence intervals for the association of  
27 prevalent hypertension with potential predictors are shown in Table 3. In multivariable  
28 logistic regression models adjusted for age, sex, parental history of hypertension, body mass  
29 index and region, the significant predictors of prevalent hypertension were male sex,  
30 increasing age, Region, parental history of hypertension, personal history of diabetes, high  
31 BMI and high waist circumference (Table 3) . In multivariable models with similar level of  
32 adjustment (Table 4), male sex, high BMI and physical inactivity were associated with poor  
33 control of hypertension, while being from Regions other than Centre or Littoral was  
34 associated with good control among treated patients (Table 4).”  
35  
36

37 Conclusions: Please rephrase the first two sentences of the conclusion as they are currently  
38 unclear.  
39  
40

41 **Our response:** The two sentences have been modified and now read:  
42  
43

44 “In conclusion, our study has provided findings that are in line with the high prevalence of  
45 hypertension previously reported in urban settings in Africa. The study further suggests that  
46 efforts to detect and treat to the targets those with the disease are still below optimal.”  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any pre-specified hypotheses	5-6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6-8
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	7-8
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	8-9
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	8-9

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	9
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	9-10
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	11
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14-15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-14
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).